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1.  SUMMARY 
 
The teneurins are a novel type II transmembrane protein family 
originally discovered in Drosophila and highly conserved between invertebrates 
and vertebrates. Studies in invertebrates suggest important functions for the 
teneurins in many processes during development. However, still very little is 
known about the biological function and mechanism of action of the vertebrate 
teneurin family, which consists of four paralogs called teneurin-1 to -4. 
 
In the first part of my thesis, I analyzed the expression pattern and 
signaling mechanism of teneurin-1 during chick development. Teneurin-1 was 
prominently expressed in specific regions of the brain, and often complementary 
to teneurin-2. The presence of teneurin-1 and -2 in interconnected regions of 
the brain implies a role for teneurins in the establishment of appropriate 
neuronal connectivity. Using a novel antibody recognizing the teneurin-1 
intracellular domain (ICD), N-terminal processing products were detected and 
nuclear staining was observed in specific neurons and tissues. This provides 
evidence for our working hypothesis, according to which teneurins can be 
processed by a mechanism called regulated intramembrane proteolysis, 
resulting in the release and nuclear translocation of the ICD. Similar results 
were obtained for teneurin-4 during chick development. 
 
In the second part of my thesis, I investigated the implication of 
teneurins in two human diseases.  
X-linked mental retardation: Teneurin-1 was analyzed as an X-linked 
mental retardation (XLMR) candidate gene in 23 XLMR patients. No mutation 
that is likely to cause the disease was found the coding region or splice sites of 
the teneurin-1 gene in these patients.  
Brain tumors: Teneurin-4 was found to be upregulated in a microarray 
analysis of human brain tumors including astrocytomas, oligodendrogliomas and 
glioblastomas (GBMs). The overexpression of teneurin-4 was confirmed on 
protein level in brain tumor lysates. Immunohistochemistry (IHC) revealed 
strong staining around tumors cells in some brain tumors whereas in others 
teneurin-4 restricted to blood vessels. 
                                                                               Introduction        
- 6 -
2. INTRODUCTION 
 
Teneurins are a family of transmembrane proteins which are thought to 
be involved in cell adhesion, which is important in many processes during 
development. Therefore, the main principles of cell adhesion will be introduced 
first. Subsequently, I will give an overview of limb and central nervous system 
(CNS) development, during both of which patterns are formed and teneurins are 
prominently expressed. Since our working hypothesis is that the teneurins are a 
substrate of regulated intramembrane proteolysis (RIP), I will dedicate one 
chapter to this signaling mechanism. In the second part of the introduction, I 
will give a background on the XLMR and on brain tumors, because I investigated 
the implication of human teneurins in these diseases. The introduction will be 
concluded by a comprehensive review of the teneurin literature. 
 
2.1 Cell-cell and cell-extracellular matrix adhesion 
 
 
In multicellular organisms, cells do not exist individually, but are 
organized in tissues and organs. To establish and maintain tissue architecture, 
cells need to adhere to each other as well as to the surrounding extracellular 
matrix (ECM). Before mature cell anchoring junctions (desmosome, 
hemidesmosome, focal adhesion, adherens junction) can be assembled, cells 
must first adhere to each other through cell adhesion molecules (CAMs), as 
summarized in Figure 1. This dynamic cell adhesion is particularly important 
during development, when cells need to migrate and adhere to the appropriate 
cells to form organs and tissues. Changes in cell adhesion are also characteristic 
for pathologic conditions such as cancer and inflammatory diseases. CAMs bind 
their ligands with much lower affinity than other cell surface receptors, but they 
are present in high concentrations. Therefore, cell adhesion depends on a large 
number of weak adhesions, which allows more dynamic regulation of cell 
adhesion. The most important families of CAMs are introduced below. 
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Figure 1: Overview Cell-Cell and Cell-ECM adhesion. 
Stable forms of cell-cell adhesion include tight junctions, the adhesion belt, desmosomes and 
gap junctions, and hemidesmosomes and focal adhesions in the case of cell-ECM adhesion. 
The major CAM families involved in dynamic are the cadherins, the selectins and the Ig-like 
CAMs mediating cell-cell adhesion, whereas the integrins and transmembrane proteoglycans 
mediate cell-ECM adhesion1. 
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2.1.1  Cell-cell adhesion 
 
The cadherins are the major CAMs responsible for holding cells together 
through Ca2+-dependent homophilic interaction. The most extensively studied 
cadherins include E-Cadherin expressed on epithelial cells and N-Cadherin 
present on nerve, muscle and lens cells, both have important functions during 
development. The classical and nonclassical cadherins, which include the 
desmosomal cadherins and the protocadherins form together the cadherin 
superfamily. All classical and some nonclassical cadherins have highly conserved 
ICDs which mediate interaction with the actin cytoskeleton through catenins, or 
with intermediate filaments in the case of desmosomal cadherins. The 
connection to the cytoskeleton is essential for the adhesive function of 
cadherins. Particularly in the central nervous system there are many different 
cadherins, each expressed in a distinct but overlapping pattern. Since they are 
concentrated on synapses, they are thought to be involved in synapse formation 
and stabilization. Some Protocadherins are also thought to contribute to the 
establishment of synaptic connectivity, because of their distinct expression 
patterns in the brain. Additional complexity is achieved by alternative splicing, 
which generates many isoforms varying in the extracellular domain (ECD). 
 
Selectins are cell-surface carbohydrate binding proteins that mediate 
transient Ca2+-dependent cell-cell adhesion in the bloodstream. They bind to 
mucins and thus mediate heterophilic interactions. L-selectin is present on white 
blood cells, P-selectin on blood platelets and on locally activated endothelial 
cells, and E-selectin on activated endothelial cells. They play important roles in 
recruitment of white blood cells to sites of inflammation. 
 
Immunoglobulin-like CAMs (Ig-CAMs) are a large family of Ca2+-
independent cell adhesion molecules containing Ig-like domains. The best 
studied example is neuronal cell adhesion molecule N-CAM, which is expressed 
in many cell types including most neurons. At least 20 isoforms of N-CAM are 
generated by alternative splicing, some having a high content of negatively 
charged sialic acid, which serves to prevent rather than promoting cell adhesion. 
Some Ig-CAMs like N-CAM mediate cell adhesion by a homophilic mechanism, 
whereas others like intercellular adhesion molecules (ICAMs) on endothelial cell 
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mediate heterophilic interactions by binding to integrins on blood cells. Since Ig-
CAM mediated adhesion is much weaker than cadherin-dependent adhesion, 
they are more involved in the fine tuning of adhesive interactions during 
development and regeneration.  
 
 
2.1.2  Cell-ECM adhesion 
 
The integrins are a family of transmembrane glycoproteins that form 
non-covalently linked heterodimers. There are genes fore 18 α- and 8 β-
subunits, which can combine to form 24 αβ-integrin receptors. Integrins are the 
principal ECM receptor on cells, since they can bind most ECM proteins including 
collagens, fibronectin and laminins. On the intracellular side, integrins interact 
with anchor proteins connecting them to the actin cytoskeleton with the 
exception of α6β4 integrin, which is found in hemidesmosomes and binds to 
intermediate filaments. Clustering of integrins mediates stronger adhesion 
through increased integrin concentration and higher ligand binding affinity. In 
addition to promoting adhesion integrins activate signaling pathways leading to 
proliferation, survival and migration. Moreover, there is crosstalk between 
integrins and growth factor receptors. Conversely, signals from inside the cell 
can modulate the ligand binding affinity of integrins and thus the ability of cells 
to adhere to the ECM. 
 
The major transmembrane proteoglyan family that mediates cell 
adhesion is the syndecan family (Syndecan-1 to -4), which are composed of a 
protein core with covalently attached heparin sulphate and chondroitin sulphate 
glycosaminoglycan sugar chains. Like integrins, syndecans can bind to many 
ECM proteins, which often have binding sites for both integrins and syndecans. 
Moreover, with their large flexible glycosaminoglycan chains, they are ideal 
receptors for growth factors that are dilute or distant from the cell membrane. 
For full spreading of cells on the ECM, both integrins and syndecans need to be 
engaged. 
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2.2 Limb development 
 
 
The formation of complex three-dimensional structures during 
development is achieved through a process called pattern formation. The limb 
buds are an excellent model to study this process, as they are not required for 
survival and can be molecularly and experimentally manipulated. Moreover, 
many key genes that control limb formation are also important in other 
developmental contexts when patterns are formed. To form a limb bud, cell 
proliferation, death and movement have to be coordinated with the assignment 
and interpretation of positional information. Cells have to be determined and 
signaling centers have to be established to provide positional information. This 
information has to be recorded by the cells, and the cells have to differentiate in 
response to additional cues. To form early limb buds, cells stard to proliferate in 
specific regions of the flank. They consist of homogenous mesenchyme cells that 
are enveloped by a layer of ectoderm. The mesenchymal cells will subsequently 
differentiate into skeletogenic mesenchyme, cartilage and tendons. Cells from 
the lateral edges of nearby somites migrate into the limb and will later generate 
the limb musculature. The apical ectodermal ridge (AER) at the distal tip is an 
important signaling center inducing proliferation of the underlying mesenchymal 
cells during limb outgrowth. To initiate AER formation, the mesenchyme signals 
to the ectoderm. Wnt signaling activates FGF10 in the mesenchyme, which 
induces AER precursors in both dorsal and ventral ectoderm to express Fgf8. 
Subsequently, the AER precursor cells migrate to the dorsal-ventral boundary at 
the distal tip of the limb bud where they undergo compaction. A second 
important signaling center is the zone of polarizing activity (ZPA) located in the 
dorsal mesenchyme of the limb bud, which is responsible for anterior/posterior 
specification. To generate a limb bud, positional information needs to be 
specified on three axes:  
 
1. Proximal-distal. Several fibroblast growth factors (FGFs) are 
specifically expressed in the AER and maintain the underlying mesenchmyal 
cells in an undifferentiated, proliferative state (Figure 2). As the limb bud is 
growing, mesenchymal cells start to condense and differentiate first into 
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cartilage and later into bone. The limb is divided in three parts, the proximal 
stylopod, the intermediate zeugopod and the distal autopod (Figure 2). 
Originally, the progress zone model was postulated, in which the time the 
mesenchymal cells spend in the progress zone under influence of the AER 
determines their proximal-distal specification. Thus, cells that leave the progress 
zone early become the stylopod, and those who leave later become the 
zeugopod and autopod. This model explains the fact that removal of the AER at 
earlier timepoints during development results in more severe truncation of the 
limb, which can be rescued by FGFs2,3. Alternatively, the early specification 
model predicts that all the proximal-distal segments (stylopod, zeugopod and 
autopod) are specified early in limb development and these progenitor pools are 
subsequently expanded as the limb bud grows out. After AER removal, the 
200μm distal-most cells undergo apoptosis; this affects a proportionally bigger 
portion of the early limb bud, this also explains a more severe truncation if the 
AER is removed early. A comparison of both models is depicted in Figure 3. In 
the past few years mouse genetics experiments have produced results that 
cannot be explained by either model; therefore neither of these models is 
entirely true. 
 
2. Anterior-Posterior. The ZPA in the posterior limb mesenchyme 
secretes the morphogen sonic hedghehog (SHH) which determines anterior-
posterior patterning (Figure 2). Cells receiving high doses of SHH adopt 
posterior fates, whereas cells further away from the ZPA adopt anterior fates. In 
the chick, transplantation of ZPA cells to the anterior limb mesenchyme or 
expression of SHH results in additional digits in a mirror-like duplication of the 
normal digits4. Genetic removal of SHH in mice leads to a dramatic loss of 
skeletal elements along the anterior-posterior axis5,6. 
 
3. Dorsal-Ventral. The information for dorsal-ventral limb patterning is already 
contained in the mesenchyme before specification of the limb bud and is 
transferred to the ectoderm as the limb bud forms. However, the molecular 
nature of this interaction is not known. When the ectoderm is rotated 180° 
respective to the mesenchyme, the mesenchymal structures become inverted 
and correspond to the polarity of the ectoderm7. Wnt7a secreted by the dorsal 
ectoderm induces Lmx1b, a transcription factor required for dorsal specification 
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of cells, in the dorsal mesenchyme. In the ventral ectoderm, the transcription 
factor Engrailed1 (En1) is induced by bone morphogenic protein (BMP) signaling 
and represses Wnt7a, which remains confined to the dorsal ectoderm (Figure 2). 
In the absence of Wnt7a dorsal patterns are not established and the limbs 
appear bi-ventral. Conversely if En1 is missing Wnt7a is misexpressed in the 
ventral ectoderm and the limb develops with bi-dorsal character8. 
 
 
 
Figure 2: Signaling pathways in vertebrate limb development. 
Chick (left) and mouse (right) skeletons showing the proximal-distal and anterior-
posterior parts of the limbs. (B) Molecular interactions that coordinate the proximal-distal 
axis under the control of FGFs and the anterior-posterior axis regulated by Shh. The 
dorsal-ventral axis is defined by BMPs and En1 in the ventral ectoderm and Wnt7a in the 
dorsal ectoderm. (C) Schematic view of the interactions between the molecules 
regulating the three axes in the limb bud9. 
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Three-dimensional growth and patterning of the limb requires 
coordinated interactions between the molecules that specify each axis. The AER 
is required for SHH expression in the ZPA, which is rapidly downregulated after 
AER removal10,11 and is absent in FGF4/FGF8 knockout mice12. Conversely, Shh 
maintains Fgf4 expression in the AER by inducing Formin, which maintains 
expression of gremlin, a BMP antagonist. Inhibition of BMP signaling by gremlin 
allows expression of FGF4 in the AER13,14. Similarly, removal of the dorsal 
ectoderm or loss of Wnt7a reduces Shh expression15,16.  
 
 
 
Figure 3: Comparison of the progress zone and early specification model. 
A) The progress zone model predicts that specification depends on the AER which 
proceeds from proximal to distal. B) The early specification model by Dudley et al. 
suggests that all fates are specified in the early limb bud, and progenitor pools are 
expanded during limb outgrowth9. 
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 Once the positional cues are provided by the established signaling 
centers, key regulatory genes must be activated in the cells to execute the 
patterning program, in particular genes of the Hox cluster. It has been shown 
that HoxD genes (Hoxd9 to Hoxd13) which are expressed at the posterior limb 
bud can be induced by combined influence of SHH and FGFs. This led to the 
suggestion that this may occur in-vivo17. However, the expression of the HoxD 
as well as HoxA genes is very dynamic during limb bud development and does 
not correlate with the anterior-posterior or proximal-distal axes. Analysis of Hox 
gene gain and loss of function suggests that the primary role of Hox genes is to 
regulate the rate and timing of cartilage proliferation and differentiation. 
Additionally, Hox genes function also at earlier stages of limb development as 
well, such as during the proliferation of undifferentiated mesenchyme, the 
condensation of mesenchmye into blastemal primordia, and the organization of 
the cartilage cells with in the skeletal elements18,19,20. It is still unknown which 
genes regulated by Hox genes exert these cellular effects. 
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2.3 Neuronal development and axon guidance 
 
2.3.1 Early neuronal development 
 
Neuronal development begins with the specification of cells in the dorsal 
ectoderm to become the neural plate. During neurulation these cells form the 
neural tube which develops into the CNS. The anterior part will become the 
brain and the posterior part the spinal cord. Neural crest cells then appear and 
start to migrate out of the dorsal neural tube. Later they will differentiate into 
the cells of the peripheral nervous system (PNS), among others. Therefore, the 
entire nervous system is derived from the ectoderm as shown in Figure 4. The 
three primary brain vesicles at the anterior end are further subdivided into five 
secondary brain vesicles (Telencephalon, Diencephalon, Mesencephalon, 
Metencephalon and Myelencephalon). The adult brain structures derived from 
each part are listed in Figure 4. This anterior-posterior pattering is directed by a 
set of genes, that includes the hox genes. The dorsal-ventral polarity of the 
neural tube is induced by signals coming from its environment. SHH secreted by 
the notochord induces ventral cell types and BMPs secreted by the dorsal 
ectoderm induces dorsal structures. Depending on the concentration and 
exposure time to these paracrine factors, different transcription factors are 
induced in the neural tube, which specify cellular identity. The original neuronal 
tube is composed of a germinal neuroepithelium, which is a layer of rapidly 
dividing neuronal cells. Their nuclei move between the luminal and external 
surface of the neural tube as they go though the cell cycle, with mitosis 
occurring at the luminal surface. Cells exit the cell cycle at a specific time point 
and begin to migrate and differentiate; this timepoint is called the birth of a 
neuron. Neurons that are born earlier migrate the shortest distance, whereas 
neurons that are born later have to migrate through the first layers to more 
superficial layers. Finally, as proliferation and differentiation proceed several 
layers of neurons are generated, forming the ventricular, intermediate and 
marginal zones. Later in development, this basic organization is maintained with 
specific modifications in the spinal cord or medulla, cerebellum and cerebral 
cortex, depicted schematically in Figure 4. 
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Figure 4: Early development of the CNS. 
(A) Ectodermal Derivatives. The ectoderm is divided into three major domains, the 
surface ectoderm (primarily epidermis), the neural crest (peripheral neurons, pigment 
cells and facial cartilage) and the neural tube (brain and spinal cord). The cell types that 
are derived from each domain are listed. (B) Early human brain development. The three 
primary brain vesicles are subdivided as development continues. The list on the right side 
indicates from which regions structures in the adult brain originate. (C) Differentiation of 
the walls of the neuronal tube. In the differentiating neural tube, three zones can be 
distinguished: the ventricular, the intermediate and the marginal zone. The spinal cord 
and medulla contains one source of neurons and glial cells, the ventricular zone. In the 
cerebellum, a second germinal zone forms within the marginal zone, from which 
neuroblasts migrate inwards to generate the internal granule cell layer. In the cerebral 
cortex, migrating neuroblasts and glioblasts form a cortical plate containing six layers21. 
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2.3.2 Development of the visual system and axon guidance 
 
The optic vesicle extends from the diencephalon and induces the lens 
placode, which invaginates to form the lens. The optic vesicle also invaginates 
and becomes the two-layered optic cup. The outer layer starts to produce 
melanin pigment and becomes the pigmented retina, and the inner layer 
containing the retinal precursor cells generates the neural retina. One retinal 
precursor cell can give rise to the six neuronal and one glial cell types, which are 
generated in an orderly manner22. First, the retinal progenitor cells expand 
through proliferation, then exit the cell cycle, commit to a particular cell fate 
and differentiate. Finally, the neural retina is organized in three nuclear layers, 
retinal ganglion cells (RGCs) reside in the ganglion cell layer (GCL), horizontal, 
amacrine, bipolar and Müller glial cells in the inner nuclear layer (INL) and rod 
and cone photoreceptors in the outer nuclear layer (ONL). Between these 
nuclear layers, there are the inner and outer plexiform layers (IPL and OPL), 
which contain axons and dendrites of the neuronal cells in the retina. The axons 
of the RGCs exit the retina together through the optic nerve and project 
primarily to the optic tectum (OT) in chicken, or to the superior colliculus (SC) 
and dorsal lateral geniculate nucleus (dLGN) in mammals. 
 
The ability of developing axons to navigate to the appropriate target is 
mediated by a specialized structure on their distal tip, the growth cone. 
Neuronal growth cones are highly motile, sensory structures that constantly 
extend and retract two types of processes: thin, finger-like filiopodia and flat, 
veil-like lamellipodia. By responding to cues in the extracellular environment, 
growth cones control the rate and direction of axon extension. The guidance 
cues can be either attractive and promote growth towards a specific region, or 
repulsive and prevent growth in a particular direction. Both type of cues can be 
associated with cell surfaces or the extracellular matrix, or be diffusible and act 
at a distance from their source. Growth cones respond to extrinsic guidance 
cues through receptors on their surface, which activate downstream signaling 
pathways that induce changes in cytoskeletal organization. Several ligands and 
corresponding receptors have been identified as key axon guidance cues. They 
include Ephrins/Ephs, netrin/Dcc, Slits/Robos and 
Semaphorins/Neuropilins/Plexins23. In addition, secreted factors known as 
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morphogens have additional roles in axon guidance, such as SHH, FGFs, BMPs 
and Wnts24. In addition, the cell adhesion molecules N-CAM, Nr-CAM, L1 and 
cadherins are involved in guiding axons. Finally, ECM proteins such as laminin, 
heparin sulphate proteoglycans (HSPGs), chondroitin sulphate proteoglycans 
(CSPGs) and metalloproteases are either directly involved in axon guidance, or 
modulate the activity of axon guidance molecules. As described in more detail in 
the next section, a small set of molecules is used at several points along the 
pathway to serve different functions.  
 
Shortly after its final cell division, an axon arises from the basal surface 
of each RGC and extends directly into the opic fiber layer (OFL), where it grows 
towards the optic disc/nerve head. The initiation of axon extension is regulated 
by integrins and cadherins25,26. As they extend to the optic disc, RGC axons are 
restricted to the OFL at the inner surface of the retina. This is regulated by 
growth promoting molecules such as NCAM present in the OFL27 as well as 
inhibitory guidance cues localized in the outer retinal layers, like Slits/Robos28. 
CSPGs present in the peripheral neuroepithelium inhibit RGC axon extension29. 
Several cell adhesion molecules, including L1, Neurolin/DM-GRASP/BEN and 
NrCAM direct growth of RGC axons towards the optic disc30,31,32,33. Additionally, 
SHH mediates disc-directed growth34. The ligand Netrin-1 is expressed by glial 
cells surrounding the optic disc and its receptor deleted in colorectal cancer 
(DCC) on RGCs; both are required for RGC axons to exit the retina35. Other 
factors contribute to targeting the RGC axons to the optic disc and mediate 
subsequent exit, such as EphBs (reverse signaling), BMP receptor 1B and 
NrCAM36,37,38,33. 
 
After leaving the eye, RGC axons grow within the developing optic stalk, 
to which they are restricted by inhibitory Semaphorin5A signaling39. In the 
ventral diencephalon, the optic nerves from both eyes meet to form the optic 
chiasm, the position of which is specified by downregulation of SHH signaling40. 
After arriving at the optic chiasm, RGC axons face the decision to cross to the 
contralateral side or to remain on the ipsilateral side. The proportion of axons 
that remain on the ipsilateral side is species-dependent and correlates with the 
extent of binocular vision. The axons that are not destined to cross the midline 
at the optic chiasm are prevented to do so by repulsion. The transcription factor 
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ZIC2 is exclusively expressed in uncrossed RGCs and correlates with EphB1 
levels, which mediates repulsion by EphrinB2 present in the midline41. Isl2, 
another transcription factor, is expressed in a distinct subset of contralaterally 
projecting RGCs and appears to be a negative regulator of ZIC2 and EphB142. 
The cell adhesion molecule NrCAM is expressed by RGCs that project 
contralaterally and at the midline and promotes axon outgrowth. Similarly, the 
secreted guidance molecule Semaphorin3D is expressed in the chiasm and 
guides RGC axons to the contralateral optic tract43. Clearly, crossing the midline 
is not a default mechanism, but an active process. 
 
Expression of growth associated protein 43 (GAP-43) is required for the 
RGCs to overcome inhibitory signals and grow from the optic chiasm into the 
optic tracts. Several molecules are involved in keeping the axons within the 
optic tract, including Slits/Robos, CSPGs, N-Cadherin, tenascin-R, secreted 
frizzled related protein 1 (SFRP1) and β1-integrin. FGF signaling is required for 
entry into the optic tectum44. As the axons reach the end of the laminin-lined 
optic tract, they spread out and find their specific targets in the optic tectum or 
superior colliculus, and a topographic map of the retina is established. Axons 
that arise from RGCs in the nasal retina project to targets at the posterior end of 
the OT/SC and dLGN, whereas axons from the temporal region of the retina 
project to the anterior end, and the same is true for the dorsal-ventral axis. The 
generation of this topographic map is mainly achieved by graded expression of 
ligands and receptors of the Ephrin/Eph family in the retina and in the OT/SC 
and dLGN, which act as chemical labels to mediate synaptic connectivity as 
proposed by Sperry45. Ephrins are membrane-bound ligands for the Eph 
receptor tyrosine kinases; therefore this signaling interaction requires cell-cell 
contact and reverse signaling can occur in the cell expressing the Ephrin 
ligands46. EphA/EphrinA signaling is required for proper mapping along the 
anterior-posterior axis, whereas EphB/ephrinB signaling patterns the medial-
lateral axis of the tectum/SC. Additionally, Ephs/Ephrins appear to be involved 
in the formation of eye-specific layers: neuronal activity segregates the axons 
from the two eyes, and EphAs/ephrinAs regulate the shape, position and size of 
the eye-specific territories47. 
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Figure 5: Key guidance cues acting in the mouse optic pathway. 
(A) Guidance within the retina towards the optic disc involves Slit/Robo, Shh and cell 
adhesion molecules, whereas Netrin/DCC is needed to exit the retina through the optic 
disc. (B) Guidance at the chiasm. Semaphorins and Slit/Robo confine the axons to the 
optic nerve. At the midline of the optic chiasm, EphrinB2 repels EphB1 expressing RGC 
axons from the ventral-temporal region of the retina, which project ipsilaterally. Nr-CAM 
present at the midline facilitates crossing of contralateral RGC axons. (C) Topographic 
mapping in the SC is achieved by gradients of Eph/Ephrin expression, which is 
counteracted by Wnt and Ryk signaling 48. 
D, dorsal, L, lateral, M, medial, N, nasal, T, temporal, V, ventral. 
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2.4 Regulated Intramembrane Proteolysis 
 
 
Proteases are classified into four general types based on their catalytic 
residues and mechanim of action, which are conserved from archea to humans: 
Serine/Threonine proteases, Cysteine proteases, Aspartyl proteases and 
Metalloproteases. Until about ten years ago, all proteases were functioning in an 
aqueous environment, which is required for the hydrolysis of peptide bonds to 
occur. The discovery of intramembrane proteases was puzzling, since they act in 
a hydrophobic environment and their substrates are transmembrane domains of 
proteins, which are typically folded into an α-helix. Therefore, intramembrane 
proteases must create a microenvironment for water and the hydrophilic 
residues needed for catalysis, and bend or unwind their substrate to access the 
peptide bonds for hydrolysis. It is an area of intense investigation how these 
proteases achieve this, especially since the essential catalytic residues are the 
same as those found in conventional proteases. 
 
Four protease families are known to date to catalyze intramembrane 
proteolysis, the Presenilins, the Site-2 Protease (S2P) family, the Rhomboids 
and the Signal-Peptide Peptidase (SPP) family (Figure 6). All of them are 
multispan transmembrane proteins with the catalytic residues located on 
different transmembrane domains, which together form the active site. Both 
Presenilins and SPPs are aspartic proteases, but their catalytic sites are oriented 
in opposite directions in the membrane and cleave accordingly oriented 
substratea. Presenilins cleave type-I transmembrane proteins, whereas SPP 
cleaves type-II transmembrane proteins. Presenilin is unique since it is 
processed into a C-terminal and N-terminal part that remain physically 
associated and contribute each one essential aspartate. In addition, Presenilin 
does not act alone but forms the γ-secretase complex together with nicastrin, 
PEN2 and APH2, whereas the other transmembrane proteases function alone. 
S2P is a metalloprotase which uses two conserved histidine and one aspartate to 
coordinate a zinc ion and cleaves type-II transmembrane proteins. Rhomboid is 
a serine protease containing the catalytic triad aspartate, histidine and serine, 
which are connected by hydrogen bonds. It cleaves type-I transmembrane 
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proteins and is the only intramembrane protease that releases extracellular 
factors instead of ICDs49. 
 
 
Figure 6: The four intramembrane protease families. 
Presenilin and Rhomboid cleave type-I transmembrane proteins, whereas S2P and signal 
peptide peptidase cleave type-II transmembrane proteins. Presenilin and SPP are both 
aspartic proteases, however their catalytic domain is oriented in the opposite direction 
and accordingly they cleave type-I and type-II transmembrane proteins, respectively. 
S2P is a metalloprotease using a zinc ion coordinated between two conserved histidines 
and an aspartate. Rhomboid is a serine protease containing a typical catalytic triad, and 
is mainly involved in the release of extracellular factors in contrast to the other 
transmembrane proteases which release intracellular signaling domains49. 
Red = catalytic residues, black = conserved motifs, green arrow = direction of substrate 
domain release. 
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To date, most of the substrates known to be processed by 
intramembrane proteolysis are type-I transmembrane proteins cleaved by γ-
secretase, including APP, Notch and the Notch ligands Delta and Jagged, ErbB4, 
CD44, E-Cadherin, N-Cadherin, Ephrins, DCC and p75NTR 50. Only ATF6 and 
SREBP are type-II transmembrane proteins cleaved by S2P in the Golgi 
apparatus. SPP also acts in the Golgi, where it clears remnant signal peptides 
from the membrane after their cleavage by signal peptidase. Therefore, type-II 
cell surface proteins have not been associated with intramembrane proteolysis, 
although it has been speculated that some may also transmit signals through 
RIP, e.g. the reverse-signaling of transmembrane forms of tumor necrosis factor 
(TNF) ligands51. The recently described SPP-like (SPPL) proteases are strong 
candidates for the cleavage of type-II plasma membrane receptors, particularly 
since members of the SPPL-family have been shown to be sorted to different 
subcellular compartments, including the plasma membrane52. Indeed, human 
SPPL2a and SPPL2b have been shown to promote intramembrane proteolysis of 
TNFα in activated dendritic cells, which leads to induction of IL-12 expression. 
Additionally, a novel splice variant of mouse SPP lacking the ER-retention signal 
was described, which localizes to the cell surface53. 
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2.5 X-linked mental retardation 
 
 
2.5.1 Definition and classification 
 
Mental retardation (MR) is a complex phenotype, defined by significant 
limitations both in intellectual functioning and in adaptive behavior as expressed 
in conceptual, social and practical adaptive skills, which originate before 18 
years of age and are not degenerative54. Recent estimates suggest that of the 
population in developed countries, 0.3% - 0.5% are affected by moderate and 
severe MR (IQ < 50), and 1-3% for mild MR (IQ 50-70)55. MR can be caused by 
both environmental and genetic factors, the former include maternal 
intoxication, prematurity, fetal infection, peri- and postnatal traumata, vascular 
accidents, asphyxia, and postnatal infections. Genetic causes comprise 
chromosomal abnormalities such as aneuploidies and microdeletions affecting 
multiple genes or mutations in a single gene. Whereas mild MR is thought to 
represent the lower end of normal IQ distribution resulting from the interactions 
of many genes and non-genetic influences, severe MR is more likely to be 
caused by specific genetic factors. XLMR is the most frequent cause of 
monogenic MR. It is inherited recessively and therefore affects mostly males, 
who are hemizygous for the mutation and inevitably affected by the disease. 
Females are usually non-manifesting carriers, but sometimes exhibit milder 
symptoms, possibly due to skewed X-inactivation. The concentration of genes 
causing MR is suggested to be twice as high on the X-chromosome compared to 
autosomes, but this might be biased by the fact that the localization of MR 
conditions to the X-Chromosome is easier due to the hemizygosity of affected 
males56. Traditionally, syndromic or specific XLMR was distinguished from non-
syndromic or non-specific XLMR based on the presence of additional 
abnormalities other than MR. This had mostly practical reasons, as in the former 
case, families affected by the same syndrome can be recognized without the 
knowledge of the causative gene, which is not possible for nonspecific MR 
families. There is however no molecular basis for this distinction, as several 
genes were found to cause both syndromic and non-syndromic forms of XLMR 
(e.g. XNP, RSK2, MECP2, SLC6A8, FLNA, ARX, PQBP1 and JARIDIC). 
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Furthermore, with the improvement of diagnostic technologies, such as 
molecular studies or brain imaging, it is likely that many non-syndromic will turn 
out to be syndromic57. 
 
 
2.5.2 How many XLMR genes? 
 
When the genetic defects of XLMR families were mapped by linkage 
analysis or using cytogenetic markers, it became evident that XLMR is a 
genetically very heterogenous disease, as the candidate intervals were non-
overlapping and distributed along the entire X-Chromosome58. Fragile-X 
syndrome accounts for 25% of the XLMR cases and results from a CGG 
trinucleotide expansion in the 5’UTR of the Fragile X mental retardation-1 
(FMR1) gene causing aberrant methylation of the promoter and loss of FMR1 
expression. The FMR1 protein associates with polyribosomes and binds to and 
regulates translation of specific mRNA’s involved in dendrite development and 
synapse function. Further, the ARX gene commonly mutated (10% of XLMR 
cases), causing several distinct XLMR syndromes as well non-syndromic XLMR, 
depending on the type of mutation. Other relatively common XLMR genes are 
JARID1C, SLC6A8 and MECP2, but the remainder of the XLMR genes is only 
rarely mutated, that is in the family where they were identified. The progress in 
identifying XLMR genes has been rapid in the past years, only 33 were known in 
2000, 45 in 2004, and to date they are 82. Figure 7 summarizes the 82 genes 
causing XLMR have been identified until 2008, indicating their position on the X-
chromosome. For 133 XLMR families, the genetic cause is still unknown59. 
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Figure 7: Known XLMR genes to date (XLMR update 2007). 
Schematic representation of the X-Chromosome indicating the positions of the 82 known 
XLMR genes. Genes in black cause syndromes, genes in gray preceded by a + cause 
neuromuscular syndromes, while genes in gray preceded by a * cause nonspecific XLMR 
conditions59. Two genes that were identified in the meantime are not represented on the 
scheme: IAP/MAGT1 at Xq21.160 and PCDH19 at Xq22.261. Source: GGC XLMR Update62. 
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The interesting question is how many XLMR genes are still to be 
discovered. There are more than 900 protein-coding genes listed in the 
ENSEMBL database on the X-chromosome, of which about 40% are expressed in 
the brain63, suggesting that the actual number of XLMR genes could possibly be 
over 200. Several strategies are used to identify new XLMR genes; the most 
comprehensive approach is high-throughput genomic DNA resequencing of all 
genes on the X-chromosome. Such studies are preformed at the Sanger 
institute with a cohort of 250 XLMR families64, or by the Euro-MRX consortium in 
a mutational screening of genes within a 7.4 Mb region in Xp1165. Both projects 
resulted in the discovery of several new XLMR genes; however it is unlikely that 
all XLMR genes will be found because certain types of mutations (e.g. 
duplications) and mutations outside the coding regions are not detected by 
these methods. A different approach is focused on candidate genes, for example 
genes that are highly expressed in the brain, paraloges of known XLMR genes, 
and genes that interact with known XLMR genes. In some cases, chromosomal 
abnormalities such as reciprocal translocations, subtelomeric translocations, and 
cryptic deletions or duplications are extremely useful to localize candidate 
genes. Recently, comparative genome hybridization technology (array-CGH) has 
been established to analyze XLMR patients. With a resolution of > 100 kb, this 
technique allows identification of cryptic deletions which were previously missed 
by standard karyotyping and subtelomeric fluorescence in-situ hybridization 
(FISH)66. Additionally, the development of a cDNA array with ~1700 expressed 
sequence tags (ESTs) corresponding to most of the protein-coding regions of 
the X-chromosome will permit the analysis of gene expression levels to find 
mutations affecting the regulatory region of the candidate gene67. Finally, 
microRNAs (miRNAs) and noncoding RNAs (ncRNAs) transcribed from the X-
chromosome could also be mutated and contribute to XLMR or other X-linked 
inherited disorders. 
 
 
2.5.3 Biological functions of MR genes 
 
It is important to keep in mind that MR is in many cases part of a 
complex syndrome comprising developmental brain abnormalities such as 
microcephaly, lissencephaly, neuronal heterotropia, agenesis, polymicrogyria 
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and schizencephaly. In these cases, the cerebral cortex lacks its normal pattern 
of organization because the responsible gene is required for normal brain 
development, and MR is a secondary symptom. In other MR conditions however, 
the brain structure and architecture appears normal and subtle defects in 
neuronal or glial cell function, morphology or interactions are responsible for the 
disease. It is suggested that in these cases, defects in synaptogenesis and 
synaptic function as well as plasticity are responsible for cognitive impairment.  
Figure 8 gives an overview of the broad range of molecular functions in which 
MR genes (including those on autosomal chromosomes) are implicated. This 
suggests that disruption of many biological processes can impair brain function. 
Surprisingly, many of the MR genes are not specifically expressed in the brain. 
This can be explained by the fact that the brain is more sensitive to damage 
because of its higher energy requirement and its susceptibility to toxic 
metabolites, therefore fundamental cellular defects that affects many tissues 
may result in MR. In contrast, other XLMR genes are expressed or function 
mainly in the brain, resulting in impairment of unique features of brain 
development or physiology68. Many XLMR genes affect gene expression, 
including genes involved in chromatin remodeling (e.g. MECP2), transcription 
factors (e.g. ARX, SOX3, ZNF genes) and RNA processing (FTSJ1) and 
regulation of translation (FMR1, RPL10). Some MR genes are implicated in 
crucial cellular processes such as DNA repair (e.g. FANCB), cell cycle regulation 
(e.g. JARID1C, DKC1), cell division (e.g. OFD1, SMC1A) and degradation of 
macromolecules through the lysosomal (e.g. ATP6AP2) or ubiquitin (e.g. UBE3A, 
MID1, CUL4B) pathway. A striking number of XLMR genes belong to metabolic 
pathways, such as glycolysis (e.g. PDHA1), urea cycle (e.g. OTC), lipid synthesis 
(e.g. HDH2, ACSL4, FACL4). Cytoskeletal components (e.g. DMD, DCX), actin 
binding (e.g. FLNA, SHROOM4) and RhoGTPase signaling genes (e.g. FGD1, 
ARHGEF9, OPHN1, AGTR, GDI1) are also affected by XLMR mutations. Several 
XLMR genes are implicated transmembrane transport (e.g. AP1S2, ATP6AP2, 
SYN1, SLC16A2, ATP7A, TIMM8A, SLC9A6, SLC6A8, ABCD1) and in signal 
transduction (e.g. RSK2, ILRAPL1, PORCN, DLG3, PAK3, MTM1), and some 
XLMR genes function in cell adhesion (e.g. NLGN2, NLGN4, L1CAM, PCDH19). A 
complete list of the 82 XLMR genes and their subcellular localization and 
function can be found in XLMR update 200759. An emerging hypothesis proposes 
that defects in synaptogenesis, synaptic activities and plasticity are the 
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underlying causes for MR, especially when gross brain abnormalities are 
absent69. Indeed, the protein products of 20 of the 82 XLMR genes (that include 
also nuclear proteins like transcription factors) localize to synapses59. Neuronal 
and synaptic remodeling occur throughout life, and abnormalities of dendritic 
spine morphology and density have been observed post mortem in MR 
patients69. 
 
 
Figure 8: Biological functions that underlie mental retardation. 
Drawing of a mammalian cortical neuron including associated structures 
(oligodendrocytes, astrocytes, blood vessels and the thyroid gland). Sizes are not to 
scale. Each of the terms in bold script represents a biological function that is affected by 
mutation of one or several MR genes68.  
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2.6.4 Teneurin-1 is a promising XLMR candidate gene 
  
We hypothesize that teneurin-1/odz1 is a promising candidate gene for 
XLMR, because it resides in Xq25, a locus of very low gene density that is 
comprised in the linkage intervals of several XLMR families. The OCRL1 gene in 
Xq25 was known to be mutated in Lowe-Syndrome70 for more than a decade; 
and since our analysis was started, two more XLMR genes in Xq25 have been 
identified: ZDHHC971, which is near OCRL1; and GRIA372, which is very close to 
teneurin-1 (ODZ1). Moreover, the teneurins are predominantly expressed in the 
developing CNS, and proposed to have a function in axon guidance and 
establishment of neuronal connectivity. SYN1 was recently identified as an XLMR 
gene73, and we found that the teneurin-1 ICD interacts with the Synapsin-1 
protein (unpublished observation). Additionally, since MECP2 is frequently 
mutated in XLMR and causes Rett syndrome74, the entire family of methyl-CpG 
binding proteins was analyzed and a nonsense mutation in MBD1 in one autistic 
and mentally retarded patient was revealed75. The MBD1 protein was shown to 
interact and colocalize in the nucleus with the teneurin-1 ICD76. Li et al suggest 
that the teneurins might be regulated by Emx277, mutations in EMX2 causes 
schizencephaly in humans because of abnormal neuronal migration in the rostral 
forebrain leading to gross morphogenetic as well as more subtle lamination 
defects78,79. Mutation of the transcriptional repressor gene ZIC2 causes MR due 
to holoprosencephaly80 (failure of right and left hemispheres to form distinct 
hemispheres), and the teneurin-2 ICD was shown to repress transcription 
mediated by another ZIC family member, ZIC181. Thus, several proteins that 
interact with teneurins are XLMR genes and therefore it is likely that teneurins 
are also implicated in pathways required for proper brain development.  
                                                                               Introduction        
- 32 -
2.6 Biology of brain tumors 
 
 
The most frequent types of brain tumors are glioma (astrocytoma, 
oligodendroglioma and oligoastrocytoma, both of which are composed of glial 
cells and occur predominantly in adults. Medulloblastoma (MB) is the most 
frequent neuronal brain tumor, which mainly affect humans early in their life 
(Figure 9). 
 
Figure 9: Developmental paths in the CNS and classification of CNS tumors. 
Multipotent neuronal stem cells residing in the ventricular (VZ) and subventricular zones 
(SVZ) of the embryonic neural tube give rise to the three major cell types in the mature 
CNS: Neurons, oligodendrocytes and astrocytes. Neuronal progenitor cells differentiate 
first into restricted progenitor cells that are competent to generate neurons or glia, 
respectively. Neuronal progenitor cells might also give rise to oligodendrocytes (dotted 
arrow). CNS tumors are classified according the cell type they resemble based on 
morphological criteria and expression of markers. Astrocytoma and Oligodendroglioma 
are both glial tumors, whereas medulloblastoma is a neuronal tumor82. 
 
 
2.6.1 Glioma 
 
Malignant gliomas are the most common primary brain tumor in adults. 
Because of diffusely infiltrative growth, they are generally not curable despite 
rigorous therapy including surgery, chemotherapy and irradiation. Gliomas are 
subdivided in astrocytomas, oligodendrocytomas and mixed oligoastrocytoma 
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based on histological appearance and expression of protein markers. 
Oligodendrogliomas tend to have better prognoses and response to 
chemotherapy than astrocytomas83. In addition, malignant gliomas are classified 
in three degrees of malignancy by the WHO: grade II, grade III (anaplastic) and 
grade IV (glioblastoma, the most aggressive form of astrocytoma). 
Glioblastomas (GBM) are very aggressively invading tumors with extremely poor 
prognosis and survival of approximately one year only. Primary GBM occurs de 
novo in the absence of pre-existing low grade lesion, mostly in older patients. In 
contrast secondary GBM evolves from lower grade astrocytoma over a period of 
5-10 years and is more frequent in younger patients84. Phenotypically, primary 
and secondary GBMs are indistinguishable, but they have distinct underlying 
genetic alterations85 (Figure 10).  
 
 
 
Figure 10: Genetic pathways in the development of primary and secondary GBM. 
Primary and secondary GBMs appear clinically and histologically indistinguishable, but 
their molecular profiles are different. A) Genetic changes in secondary astrocytoma 
include those required for tumor initiation (TP53 loss, PDGF autocrine loop) and those 
involved in tumor progression (mutations in the Rb pathway: eg. loss of Rb, CDK4 
amplification). B) Deletion INK4A locus is very common in primary GBM, which results in 
the simultaneous loss of p16 (an effector of the Rb pathway inducing cell cycle arrest) 
and ARF (which stabilizes p53 by sequestering mdm2). The disruption of both crucial 
tumor suppressor pathways at the same time is thought to be a reason for the rapid 
development of primary GBM. Additionally, mutation or amplification of the EGFR and 
loss of PTEN are more frequent in primary GBM82. 
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For a long time, it was postulated that astrocytoma arises from 
astrocytes and oligodendroglioma from oligodendrocytes, however most cells in 
the brain do not normally undergo cell division which is a prerequisite for 
transformation, except during reactive proliferation after trauma83,86 . Therefore, 
the idea of a “window of neoplastic vulnerability” was described, in which 
oncogenic events may occur in still proliferating fetal cells. This is in accordance 
with the fact that neuronal tumors are uncommon and occur early in life, when 
neuronal cells are still dividing. Glioma in contrast is more common and occurs 
in adults, because glial cell proliferation occurs later in development and for a 
more prolonged period. Alternatively, recent work in animal models and primary 
glioma suggests that malignant glioma arises from neural progenitor cells. 
These cells reside in the ventricular zone of the adult brain and share important 
characteristics with glioma cells: Proliferative potential, migratory capacity, and 
competence to differentiate into different cell types. Mouse models expressing 
activated RAS and AKT in specific cell types revealed that glial progenitors are 
more sensitive to transformation than more mature astrocytic cells82. 
Alternatively, it was demonstrated that loss of CDNK2A/p16 can confer a more 
progenitor-like phenotype to astrocytic cells87. The cancer stem cell hypothesis 
suggests that tumors are maintained only by a rare fraction of cells with stem 
cell properties, as it has been shown in hematologic malignancies and several 
solid tumors. Likewise, gliomas contain a subpopulation of cells which are 
CD133+ and have the capacity to self-renew and undergo lineage-specific 
differentiation. Orthotopic injection of CD133+ cells results in tumors displaying 
the same cellular heterogeneity as the original tumor, but CD133- cells fail to 
form tumors88. 
 
The p53 pathway is commonly disrupted in astrocytoma; p53 itself is 
mutated in 50% of the tumors, and in most others p53 activity is downregulated 
by amplification of MDM2 or MDM4 or loss of ARF (which sequesters MDM2). In 
addition, many growth factors are overexpressed in early stage astrocytomas, 
including epidermal growth factor (EGF), FGFs, vascular endothelial growth 
factor (VEGF) and platelet derived growth factor (PDGF). In the case of PDGF 
both the ligand and receptor are overexpressed resulting in an autocrine loop. 
Oligodendrogliomas exhibit coordinated loss of chromosomes 1p and 19q in 40-
80% of the cases, however the identity of the tumor suppressor genes located 
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there is unknown. Although oligoastrocytomas exhibit mixed phenotypic 
appearance, their genetic background resembles either oligodendrogliomas (loss 
of 1p and 19q), or astrocytomas (TP53 mutations). Either the type of oncogenic 
alteration can dictate the tumor phenotype, as in the glioma mouse model 
where overexpression of Ras and Akt in progenitor cells results in astrocytic 
tumors, but overexpression of PDGF-B in the same cells generates 
oligodendrogliomas89. Alternatively, the phenotypic repertoire of the cells 
undergoing transformation and the cerebral environment may also influence 
tumor differentiation. During progression from grade II to grade III, gliomas 
acquire genetic lesions affecting cell cycle control, such as loss of p16 or pRb, or 
alternatively by overexpression of CDK4, CDK6 or cyclin D1. In about 50% of 
anaplastic astrocytomas and glioblastomas, deletions in chromosome 9p 
encompassing the CDKN2A locus result in the loss of p16 and ARF proteins, or 
the CDKN2A gene is inactivated by point mutations or hypermethylation90. 
Deletions of 13q affecting the RB gene is detected in 30-50% of high-grade 
astrocytomas, and rarely occurs together with loss of CDKN2A in the same 
tumor91. Loss of PTEN due to deletions of chromosome 10 or inactivating 
mutations (20%) lead to downstream activation of the AKT pathway, as it is 
observed in almost all glioblastomas92. In addition, upregulation of the RAS 
pathway by EGFR overexpression mediated by Shc and Grb2 is crucial for glioma 
progression facilitating proliferation, survival and angiogenesis. 
 
The main reason for poor prognosis for glioma patients is the 
invasiveness of glioma cells, which is already acquired early in tumorigenesis 
and requires a dynamic interplay between cell-cell adhesion, ECM remodeling 
and cell motility. Secretion of extracellular proteases by glioma cells not only 
clears the path for migration, but also releases growth factors that are 
sequestered in the ECM and generates growth-promoting ECM fragments93. 
Several integrin have been implicated in glioma migration, including α2β1, α5β1, 
α6β1, α5β3, which interact with tenascin, fibronectin, laminin and vitronectin, 
some of which are also produced by the tumor cells94. Both EGFR and integrins 
signaling activates focal adhesion kinase (FAK), which stimulates pathways 
leading to proliferation, survival and migration95. In addition, FGF, EGF and 
VEGF expressed by astrocytic gliomas likewise stimulate migration. In 
particular, clusters of tumor cells with EGFR amplification were preferentially 
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localized to infiltrating edges of glioblastomas96, and some gliomas express a 
constitutively active EGFR mutant (vIII EGFR)97. The ECM in the brain is rather 
scarce, and basement membranes are only around blood vessels and the pial 
surface. Therefore glioma migration exhibits specific characteristics: Cells 
preferentially invade along white matter tracts, often cross the corpus callosum 
to form “butterfly lesions” affecting both brain hemispheres, and some gliomas 
stop growing abruptly at the border between white and grey matter junction. In 
the grey matter, glioma cells prefer to grow either around neurons, blood 
vessels or underneath the pial surface. Necrosis is a prominent feature of high-
grade gliomas and predicts poor outcome. Small areas of necrosis can develop 
in areas where the metabolic demands of rapidly growing tumor cells exceed 
nutrient supply, and larger necroses arise from vascular thrombosis, possibly 
caused by the tumor secreted tissue factor, which acts as a local coagulant. It is 
suggested that hypoxia promotes acquisition of molecular changes which result 
in more active migration, and necrotic cells may release growth factors. 
Importantly, hypoxia may select for very malignant cells that are resistant to 
apoptosis98. Two different types of vascular proliferation are observed in 
glioblastoma, microvascular proliferation and a diffuse increase in vascular 
density consisting of more densely arranged small vessels. Glomeruloid vessels 
are a characteristic form of microvasular proliferation consisting of proliferating 
endothelial and smooth muscle cells and often surround regions of necrosis. 
Tumor cells release VEGF and PDGF, which stimulate proliferation of VEGFR1, 
VEGFR2 and PDGFβ-receptor expressing endothelial cells. VEGF is the major 
factor for glioblastoma angiogenesis, downstream of both crucial signaling 
pathways activated in glioblastomas, EGFR and AKT, and may also induced by 
hypoxia99. Additionally, VEGF enhances vascular permeability, resulting in 
leakage of the blood-brain barrier and tumor edema.  
 
 
2.6.2 Medulloblastoma 
 
Medulloblastoma, the most common pediatric brain tumor, is a malignant 
invasive neoplasm of the cerebellum composed of primitive neuroectodermal 
cells, but often contain glial cells as well100. As with glial tumors, there is a lot of 
debate about the cell of origin. The cerebellum contains two distinct germinal 
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zones, the VZ which generates both neurons and glia, and the external germinal 
layer (EGL) which generates primarily neuronally restricted granule cell 
precursors. It is not clear from which layer MB’s arise, there is evidence for both 
and human MBs express either VZ or EGL markers. There are two major 
subclasses of MB’s described as either “desmoplastic” or “classic”. Desmoplastic 
tumors occur in 15-20% of patients, more often in adults, and are located in the 
cerebellar hemispheres, display relatively favorable prognosis. 75-80% of MBs 
are classic MB’s, which are located at the center of the cerebellum and grow in 
relatively uniform sheets of cells with high nuclear/cytoplasmic ration, and have 
a tendence to invade adjacent brain and leptomeninges101. Like gliomas, MB’s 
contain cells expressing the stem cell marker CD133, which can form 
neurospheres, undergo self-renewal, can be induced to differentiate into both 
neurons and glia, and can generate tumors after transplantation into 
immunocompromised mice. 
 
Two signaling pathways are crucial for MD development, SHH and Wnt 
signaling. Patients with the Gorlin syndrome have activating mutations in the 
SHH receptor patched, and exhibit recurrend basal cell carcinomas of the skin, 
craniofacial abnormalities, and increased incidence of MB102. Additionally, 20-
30% of sporadic MBs harbor activating mutations of the SHH pathway, and mice 
with activating patched mutations develop MB103. SHH signaling is known to 
control proliferation of granule cell precursors (GCPs)104 and influence 
multipotent neuronal stem cell growth105. Humans with the Turcot’s syndrome 
caused by a germline mutation in the adenomatous polyopsis coli gene (APC) 
have a high incidence of colon cancer and brain tumors, which are mostly 
MBs106. Sporadic MBs rarely carry mutations in APC, but 5 to 15% of tumors 
have mutations β-catenin and axin, which also lead to activation of the Wnt 
pathway107. Unlike the SHH pathway, the WNT pathway was not implicated in 
the growth or survival of GCPs. However it is critical for the specification of the 
midbrain-hindbrain boundary from which the entire cerebellum develops, ant 
therefore may be important for the growth and survival of multipotent 
progenitors108.  
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2.7 The teneurins – an emerging family of 
transmembrane proteins 
 
 
The teneurin protein family is highly conserved from invertebrates to 
vertebrates, both regarding domain architecture and amino acid sequence. 
Moreover, the teneurin expression patterns are conserved across phyla, 
suggesting that this is also the case for their function. Since most of the data 
available for vertebrate teneurins are limited to expression patterns and in-vitro 
studies, I will first describe the expression pattern and the phenotypes of 
teneurin mutants in invertebrates.  
 
 
2.7.1 Invertebrate Teneurins 
 
The Teneurins were initially discovered in Drosophila melanogaster by 
two independent groups, one searching for orthologs of the vertebrate tenascin 
protein family109, and one performing a screen for tyrosine phosphorlyated 
proteins110. Both groups reported expression of ten-m/odz oz (odz) in 
alternating parasegments during the blastoderm stage, and loss of function 
resulted in a pair-rule phenotype with missing alternative parasegments and 
fused denticle belts. This was surprising for a gene causing a pair-rule 
phenotype as all other known pair-rule genes encode transcription factors. In 
Drosophila, segmentation along the anterior-posterior axis is initiated by 
maternal genes, which then activate zygotic genes which act in a stepwise, 
hierarchical manner. Gap genes activate pair rule genes, which subsequently 
activate segment polarity genes. Baumgartner et al. suggested that ten-m/odz 
acts as a secondary pair rule gene downstream of the pair-rule genes ftz and 
eve, and upstream of the segment polarity genes prd (paired), slp1 (sloppy 
paired 1), gsb (gooseberry), en (engrailed) and wg (wingless). Levine et al. 
describe ten-m/odz as a late acting pair-rule gene, which is expressed just as 
the syncytial blastoderm becomes transformed into the cellular blastoderm in 
which cell-cell communication can take place. Many genes involved in pattern 
formation during embryogenesis are also important in morphogenetic processes 
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occurring at later stages in development, this appears to be true also for the 
teneurins. During embryonic development, ten-m/odz is expressed in cardiac 
cells, in the lymph gland, and in the tracheal system as well as in all segmental 
furrows that fold during gastrulation (cephalic furrow, anterior and posterior 
transverse fold and posterior midgut plate). After hatching and during larval 
development, ten-m/odz is present in the ventral nerve cord, in the brain, in 
pioneering commissural axons, in cardiac cells, in lymph glands, in the tracheal 
system, around muscle attachment sites and in the visceral mesoderm. Ten-
m/odz is particularly strongly expressed in the developing eye during pupal 
stages. A very distinct ten-m/odz expression pattern has been described in all 
imaginal discs of Drosophila larvae. In the eye imaginal disc, ten-m/odz is 
present in the morphogenetic furrow which implies a function in differentiation 
of imaginal disc cells. As ommatidia mature, ten-m/odz is expressed in the 
photoreceptor R7 and may be involved in specification of this cell. Mutations in 
ten-m/odz result in R7 photoreceptor and visible light photoreceptor loss and 
defects in ommatidial size, shape and rotation, ommatidial disorder and fusion, 
and interommatidial bristle defects111. Expression of the ten-m and its paralog 
ten-a are largely overlapping, suggesting that both proteins may act 
cooperatively. Although ten-a mutants alone do not show a pair-rule phenotype, 
the phenotype of ten-m/odz mutants is enhanced and they exhibit very similar 
defects in eye patterning112. 
 
In Caenorrhaditis elegans, there is only one gene named ten-1, from 
which two isoforms are generated by the use of alternative promoters. The long 
form Ten-1L corresponds to the full length protein, whereas the short form Ten-
1S is missing most of the N-terminal ICD. Both isoforms have distinct 
expression patterns: Ten-1L is mainly found in the mesoderm, including 
pharynx, somatic gonad, various muscles and in neurons, whereas Ten-1S is 
predominantly expressed in some hypodermal cells and in a subset of neurons. 
The in-vivo function of ten-1 was analyzed using deletion mutant and siRNA, 
which resulted in a pleiotrophic phenotype including gonad disorganization, 
nerve cord defasciculation and defects in distal tip cell migration and axonal 
pathfinding113. More detailed analyses gonad rupture and germ cell leakage 
phenotype revealed that it is caused by a defect in the integrity of the basement 
membrane (BM) surrounding the gonad. Moreover, ten-1 was shown to 
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genetically interact with the genes for the BM proteins nid-1 (nidogen) and epi-1 
(laminin α-chain) as well as with the cell-surface BM receptors ina-1 (integrinα) 
and dgn-1 (dystroglyan)114. 
 
 
2.7.2 Vertebrate Teneurins 
 
Vertebrate teneurins are between 30-40% conserved compared to both 
fly and worm teneurins. In vertebrates, four teneurin paralogs called teneurin-1 
to -4 (or ten_m1 to ten_m4 in the mouse) exist, which share a conserved 
domain architecture and amino acid identity of 60-70%. The teneurins are type 
II transmembrane proteins with a molecular weight of more than 300kDa 
containing an N-terminal ICD, a single span transmembrane domain (TM) and a 
large C-terminal ECD which is particularly well conserved. The ICD contains two 
EF-hand like motifs, two polyproline motifs and several conserved tyrosines 
which are predicted to be phosphorylated. On the extracellular side, there are 
eight tenascin-type EGF-like repeats followed by a region of highly conserved 
cysteines and the unique YD-repeats which do not occur in any other eukaryotic 
protein (Figure 11).  
 
 
Figure 11: Domain architecture of vertebrate teneurins. 
Teneurins have an N-terminal ICD, a single-span transmembrane domain TM and a large 
ECD. The ICD contains two EF-hand like motifs (EF), two polyproline motifs (PP) and 
several conserved tyrosines (Y) that are predicted to be phosphorylated. The ECD 
consists of eight tenascin-type EGF-like repeats, a region of conserved cysteines, and the 
unique YD repeats. Arrows with numbers indicate postulated cleavage sites: 1. Cleavage 
site for ectodomain shedding, 2. Transmembrane cleavage site resulting in the release of 
the ICD, and 3. C-terminal cleavage site resulting in the release of the TCAP115. 
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Several postulated cleavage sites are present in teneurins: There is a 
conserved furin cleavage site between the TM domain and EGF-like repeats, 
which was shown to be functional in teneurin-2116. The resulting ectodomain 
shedding appears to take place in vivo, since an antibody recognizing the 
teneurin-2 EGF-like repeats labels both the cell surface and the extracellular 
matrix in the chick embryo117. This cleavage site is conserved in invertebrate 
teneurins, suggesting that ectodomain shedding is important for the function of 
teneurins. A putative cleavage site within or near the TM domain serves to 
release the teneurin ICD. Finally, there is a conserved furin cleavage site near 
the C-terminus, which was proposed to release the teneurin C-terminal 
associated peptide (TCAP), with neuromodulatory activity118. Many ECM proteins 
are built by a combination of domain modules, for example Tenacin-C for which 
individual domains have distinct functions119. The modular domain composition 
of the teneurins and the evidence for proteolytic processing suggest that 
different domain of the teneurins could act separately to mediate distinct 
teneurin functions. The teneurins are posttranslationally modified by 
glycosylation, as treatment with N-glycosidase F alters their electrophoretic 
mobility120. The Teneurin EGF-like repeats are most closely related to those of 
Tenascin-C and Notch; which in the case of Notch are glycosylated by Fringe. 
This posttranslational modification is required for proper ligand interaction and 
Notch signaling121,122,123. In a database search, the EGF-repeats of all four 
Teneurins and Tenascin-C were found to contain a protein-O-fucosyltransferase-
1 (POFUT1) consensus site and therefore are predicted to be O-fucosylated124. 
Additionally, the YD–repeats are predicted to be glycoslyated, and 
recombinantly expressed YD-repeats have been shown to bind the 
glycosaminoglycan heparin125.  
 
All studies investigating the expression of vertebrate teneurins performed 
in mice, chicken and zebrafish agree that the teneurins are prominently 
expressed in the developing central nervous system, but are also present at 
other sites of morphogenesis. The expression pattern of vertebrate teneurins is 
strikingly similar to teneurin expression in Drosophila; particularly remarkable 
examples include the expression during invertebrate and vertebrate eye 
development and the expression in fly leg imaginal discs and the limb buds of 
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chicken and mice. A summary of teneurin expression profiles described to date 
is provided in Table 1.  
 
Table 1: Summary teneurin expression in vertebrates 
1Ben-Zur et al. 2000126, 2Kenzelmann et al. 2008127, 3Leamey et al. 2007a128, 4Leamey et 
al. 2007b129, 5Li et al. 200677, 6Lossie et al. 2004130, 7Mieda et al. 1999, 8Minet et al. 
1999131, 9Oohashi et al. 1999132, 10Rubin et al. 1999116, 11Tucker et al. 2000133, 12Tucker 
et al. 2001117, 13Zhou et al. 2003134. 
zebrafish  
teneurin-1 ND 
teneurin-2 ND 
teneurin-3 developing brain7, somites7, notochord7, pharyngeal arches7 
teneurin-4 developing brain7, spinal cord7 
  chicken  
teneurin-1 developing CNS2,8,10, visual system2,8,10 
teneurin-2 
developing CNS10,12, visual system10, AER of limb buds12, 
tendon primordia12, pharyngeal arches12, heart12, somites12, 
neural tube12, craniofacial mesenchyme12 
teneurin-3 ND 
teneurin-4 developing CNS11, ZPA of limb buds11, pharyngeal arches11 
  
mouse  
teneurin-1 
developing and adult CNS5,9,14, visual system5,9, smooth 
muscle cells in lungs9, kidney glomeruli9, adult testes9 
teneurin-2 developing and adult CNS14, visual system5 
teneurin-3 
developing and adult CNS1,2,3,5,13,14, visual system1,5, spinal 
cord1,14, notochord14, craniofacial mesenchyme1, tongue1, 
dermis1, saccule1, developing limb1, periosteum1 
teneurin-4 
developing and adult CNS1,5,6,14, visual system5, somites14, 
spinal cord1, trachea1, nasal epithelium1, saccule1, joints1, 
adipose tissue1, tail bud and limbs6 
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An early study of neurestin (rat teneurin-2) called shows expression in 
the developing olfactory bulb, which persists in the continuously regenerating 
granule cells. Since expression in tufted cells is re-induced during olfactory bulb 
regeneration after injury, the authors speculate that neurestin is involved in 
neuronal development and regeneration. Neurestin expression also persisted in 
hippocampal granule cells, which are known to be generated throughout life135. 
In a microarray study, teneurin-4 was also shown to be expressed in the 
regenerating olfactory bulb, suggesting that the teneurins might not only be 
important during neuronal development, but also during neuronal 
regeneration136. 
 
 A few studies have addressed the function of teneurins using cell culture 
or biochemical assays. Explanted chick dorsal root ganglia were induced to grow 
neurites which tended to fasciculate when plated on teneurin-1 YD-repeats125. 
In transfected Nb2a cells, full-length teneurin-2 induced an increased number of 
filopodia and enlarged growth cones116, and this effect was shown to be 
dependent on the presence of the ICD137. The ICD of teneurin-1 was shown to 
interact with the adaptor protein CAP/Ponsin, which could represent a possible 
link to the actin cytoskeleton76. Moving filopodia left a trace of teneurin-2 
behind, suggesting that the ECD is cleaved and deposited on the substrate. The 
induction of neurite outgrowth was enhanced on laminin compared to 
polylysine, suggesting that teneurin-2 interacts with laminin116. This idea is 
further substantiated by the colocalization of ten-2 ECD with laminin in the 
basement membrane of some tissues117. Several experiments suggest that the 
teneurins promote homophilic interactions between cells. Overexpression of a 
teneurin-2 construct missing the ICD in HT1080 cells resulted in cell 
aggregation, and if the cells were grown in a monolayer they exhibited epithelial 
morphology and teneurin-2 was highly enriched at sites of cell-cell contact137. 
Recombinant proteins consisting of the ten_m1 EGF-like repeats were shown to 
dimerize, possibly mediated by the odd number of cysteines present in the EGF-
like repeat, which allows for the formation of intrermolecular disulfide bonds. 
Additionally, a recombinant ten_m1 ECD fused to Alkaline Phosphatase was 
used to detect teneurin binding activity on tissue sections, which largely 
overlapped with the ten_m1 expression domain, suggesting that homophilic 
interaction takes place. The homophilic binding of ten_m1 could be confirmed 
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on a far western blot (WB)132. Electron microscopy analysis of purified and 
rotatory shadowed teneurin ECDs revealed dimers with a C-terminal globular 
domain for all four mouse teneurins. Furthermore, co-expression of different 
teneurin paralogs in cell culture suggests heterophilic interaction. However if 
this occurs at physiological expression levels remains to be shown120. 
 
Some experiments suggest that the Teneurin ICD may have 
transcriptional activity: Transfected teneurin-2 ICD colocalized with PML bodies 
in the nucleus, and cotransfection of ZIC2 led to a proteasome-dependent 
decrease of teneurin-2 ICD protein levels. Conversely, expression of teneurin-2 
ICD inhibited the transcriptional activation of ZIC2 as determined by a reporter 
assay81. When a recombinant protein with a transcriptional activator domain 
fused to the teneurin-2 ICD was expressed in cells, transcription of a luciferase 
reporter can be detected, indicating that the ICD is released from the 
membrane. Luciferase activity was enhanced 6.5 fold by cotransfection of a 
teneurin-2 construct containing only the TM domain and ECD, which simulates 
homophilic interaction81. The availability of antibodies recognizing the N-
terminus of teneurin-1 enabled detection of ICD in the nucleus of cells that 
overxpressed full-length teneurin-1 by subcellular fractionation and WB analysis. 
Moreover, the ICD was found to interact with the methyl-CpG-binding protein 
MBD1, which could mediate teneurin-dependent modulation of gene 
expression76. 
 
Recently, two studies of mouse ten_m3 in mice shed light on the in-vivo 
function of vertebrate teneurins. In a micoarray study comparing the gene 
expression between the visual and somatosensory cortex at time of 
establishment of neuronal connectivity, several teneurins (ten_m2, ten_m3 and 
ten_m4) were found to be specific for the visual cortex. Further experiments 
demonstrated that the cell bodies of neurons transfected in utero with GFP-
ten_m3 tend to aggregate and exhibit increased neurite outgrowth that persists 
during development128. The same group published the first analysis of a teneurin 
knock-out mouse. In the visual pathway, most of the axons of the RGCs cross 
the midline of the optic chiasm and project to the contralateral dLGN, with the 
exception of a subset of RGCs that does not cross the midline and projects to 
the ipsilateral dLGN. The proportion of uncrossed projections varies among 
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species and correlates with the extent of binocular vision. Ten_m3 knockout 
mice do not exhibit an overt phenotype, and their brain and visual system 
appear normal on anatomical and histological level. However, the mice lacking 
teneurin-3 have defects in RGC axon targeting of the ipsilateral projections, 
resulting in an impairment of binocular vision. The authors conclude that 
ten_m3 is the first molecule that was shown to affect only ipsilateral, but not 
contralateral RGC axon guidance129,138.  
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3. AIM OF MY WORK 
 
 
 Teneurins are a unique transmembrane protein family, conserved from 
flies and worms to vertebrates. Analysis of teneurin expression and function in 
invertebrates suggests important functions in many processes during 
development. However, still very little is known about the biological function and 
mechanism of action of the vertebrate teneurin family, which consists of four 
paralogs called teneurin-1 to -4. 
  
 
The goal of the first part of this thesis was to gain insights in the function and 
signaling mechanism of the vertebrate teneurins using the chick embryo and 
cultured cells as a model system.  
  
 
 In the second part, the aim was to investigate the implication of 
teneurins in human disease. Teneurin-1 is localized on the X-chromosome, and I 
analyzed it as a candidate gene for XLMR. Additionally, a microarray study 
suggested that teneurin-4 was overexpressed in brain tumors, and therefore I 
generated the tools to analyze teneurin-4 in brain tumor samples.  
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4. MATERIALS AND METHODS 
 
 
4.1 Production of antibodies against chicken teneurin-4 
 
 RT-PCR was performed on chick brain RNA using the Superscript RT-PCR 
kit (Invitrogen) and oligodT primers. The obtained cDNA was subsequently used 
as a template for PCR amplification of chick teneurin-4 sequences. 
 
4.1.1 ICD antibody 
 
 A fragment corresponding to the first two exons of chick teneurin-4 was 
amplified using the Hi-Fi Expand Kit (Roche), standard PCR conditions (Ta = 
55°C and Te = 45s) and the primers cten4 fw SphI: 
ACTAGCATGCGATGTAAAAGAAAGGAAACCG and cten4 rev KpnI: 
TAGTGGTACCAGTTTCGGTATTCTCGTGCTC. The resulting PCR fragment was 
cloned SphI-KpnI into the PQE30 vector (Qiagen) containing a C-terminal HIS-
tag for protein expression and purification in bacteria. M15 Prep4 bacteria were 
transformed with the cten-4 ICD construct, and protein expression was verified 
by SDS-PAGE (Acrylamid (BioRad), APS (Sigma), TEMED (Sigma) followed by 
Coomassie staining (Pierce). The cten-4 recombinant protein was found in the 
soluble fraction and therefore purified under native conditions. 50 ml of bacterial 
culture in 2YT medium were induced for protein production, and the lysate was 
prepared. The HIS-tagged recombinant protein was bound on a ProBond Nickel-
Column (Invitrogen) and eluted with increasing concentrations of Imidazole 
(Fluka) according to the Qiagen Expressionist protocol. The purified protein was 
sent for injection into rabbits (RCC) to generate polyclonal antibodies, and the 
resulting antibodies were tested on recombinant protein. 
 
4.1.2 ECD antibody 
 
 A recombinant fusion protein between the Tenascin-C signal peptide and 
the chick teneurin-4 EGF-like repeats was generated by splicing by overlap 
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extension. The TNC fragment was produced from the pCTN-230 plasmid using 
the primers KS fw: CGAGGTCGACGGTATCG and TNC/cten4 EGF rev: 
ACAATTATCCACTGATTCATTGAGCCCAGTCTCCCG and the cten4 EGF fragment 
using the primers TNC/cten4 EGF fw: CGGGAGACTGGGCTCAATGAATCAGTGGAT 
AATTGT and cten4 EGF rev: TAGTCTGGAGTTAGTGATGGTGATGGTGATGTCCATC 
GTTGTCCTTCCCGTC containing a HIS tag and XhoI site. To obtain the fusion 
protein, a second PCR was performed using both fragments as template and the 
KS fw and EGF rev primers. The resulting PCR fragment was cloned into the 
pCEP-Pu vector using the restriction enzymes NotI and XhoI and sequenced. 
Expression and secretion of the recombinant protein in 293T-EBNA cells was 
verified by WB analysis of cell lysates and cell culture medium using the penta-
HIS antibody (Qiagen). Cells stably expressing the TNC/hten4 EGF protein were 
selected with G418 for the EBNA-plasmid (Promega) and Puromycin for the 
pCEP plasmid (Sigma). These cells were finally grown in 0.3% FCS in triple 
flasks (Nunc) to produce and secrete the TNC/cten4 EGF protein. Subsequently, 
the recombinant protein was purified from the tissue culture medium and sent 
for injection into rabbits to generate polyclonal antibodies. The antibodies were 
first tested on recombinant protein, and subsequently on cell and tissue lysates. 
 
 
4.2 IHC of developing chick embryos 
 
 Chicken embryos were incubated and sacrificed on the appropriate day of 
development to prepare tissue sections as previously described127. The sections 
were rinsed in PBS, blocked with BSA (Sigma) and stained with the cten4 NA 
(1:500), cten4 EGFA (1:500) and cten4 EGFB (1:500) antibodies overnight. 
Secondary FITC-labeled antibodies (Alexa) were used at a concentration of 
1:1000 and the nuclei counterstained with Hoechst 33342 (Sigma) used 1:1000. 
As control, the preimmune serum or the secondary antibody alone were used to 
stain the sections. The sections were viewed on a Zeiss Z1 and images were 
acquired using the Image Access software. 
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4.3 WB analysis of developing chick embryos 
 
 Chicken embryos were sacrificed and the brains, eyes, limb buds and 
organs were dissected out. RIPA buffer (50mM Tris (Fluka), 150mM NaCl 
(Fluka), 0.1% SDS (BioRad), 0.5% Na-Deoxycholate (Merck), 1% Triton-X 
(Fluka)) was added and the tissues were homogenized with a small pestle. The 
lysates were clarified by centrifugation and the protein concentration 
determined by a Bradford Assay (BioRad). The samples were analyzed on a 
7.5% Polyacrylamid-gel, blotted for 2h at 45 mA per minigel using a semi-dry 
blotting system (Millipore). The blots were stained with amidoblack to check the 
amount of protein on the membrane, and blocked with 5% milk (Fluka). The 
membranes were incubated overnight with cten4 Ab’s at the following 
concentrations: cten4 NA (1:500), cten4 EGFA (1:1000) and cten4 EGFB 
(1:1000). Blots were washed in TBS-T (TBS containing 0.1% Tween (Fluka)) 
and incubated with HRP-labeled secondary antibody (Cappel) diluted 1:1000 
and washed again. Chicken teneurin-4 was detected by Super Signal (Pierce) 
and recorded on a HyperfilmTM (Amersham). As a loading control, human β-actin 
antibodies (Sigma) were used that crossreacted with chicken β-actin. 
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4.4 Sequencing of human teneurin-1 
 
4.4.1 Patient samples 
 
 Literature search was performed to identify XLMR families with a linkage 
interval containing Xq25, and the European MRX-consortium and the Greenwood 
Genetic Center were contacted to ask for DNA samples of XLMR families linked 
to Xq25 with unknown cause of the disease. Three healthy control samples were 
obtained from the blood of volunteers after purification of genomic DNA from 
white blood cells using the QiAamp DNA Blood Mini Kit (Qiagen). All patients 
that were sequenced are listed in Table 2. 
 
Euro-MRX Consortium No DNA No
a D004 12318
b L022 22317
c L025 23402
d L041 15363
e N005 5309
f N043 4235
g P003 10644
h P004 10651
i P014 10655
j T013 22408
k T019 10963
l T048 21236
GGC Family Sample No
m K8245 5897
n K8310 8038
o K8895 cms1438
p K8917 cms2497
q K8923 cms2605
r K8941 cms3181
s K8943 cms3235
t K9033 cms6176
other source
u Italian patient
v English patient
w Brazilian patient  
 
Table 2: List of samples from XLMR families.  
Samples from the Euro-MRX consortium were obtained from Arjan de Brouwer, samples 
from the Greenwood Genetic Center (GGC) were obtained from Dr.Charles Schwartz and 
Dr. Anand Sristava. The Italian patient was obtained from Dr. Alessandra Renieri, the 
English patient from Dr. Deirdre Cilliers139 and the Brazilian patient from Dr. Fernando 
Kok140. 
                                                                Materials and Methods        
  
- 51 -
4.4.2 PCR and sequencing primers 
 
 All exons according to transcript number NM_014253 were analyzed. A 
list of the PCR and sequencing primers used is provided in Table 3. If possible, 
different primers were used for PCR and sequencing, however in cases where it 
was difficult to find a primer that works, the PCR primer was reused for 
sequencing. Several sequencing primers hat to be used for exon 1 including the 
putative promoter region, exon 27 and exon 31 including the 3’UTR several 
sequencing primers due to their size. Genomic DNA from XLMR patients and 
controls was used as the template. Standard PCR conditions were applied if not 
otherwise indicated, using the HiFi PCR kit, Ta of 55°C, te of 45s and 25 cycles of 
PCR. In some cases, the Expand Long Template kit (Roche) was used with the 
according DNA polymerase and the ELT-buffer mentioned. The PCR conditions 
for each exon were first set up using the control samples before PCR on XLMR 
patient samples were performed. PCR reactions were purified using the PCR 
purification Kit (Qiagen). For sequencing, an appropriate amount of PCR product 
(depending on its size) was combined with 10nM of primer and submitted to the 
sequencing facility at the FMI. 
 
4.4.3 Sequence analysis 
 
 DNA sequencing was carried out at the FMI sequencing facility on an ABI 
PRISM 3700 DNA Analyzer and both the sequence in text format and the 
chromatogram were obtained. The irregular sequence in the beginning and after 
the end of the PCR product for each was cropped and all the exons of one 
patient were composed to one sequence for each patient. Subsequently the 
sequences of the 23 patients and 3 controls were aligned using the ClustalW 
program141 to find alterations. To exclude misinterpretation of the 
chromatogram by the sequence analysis program, the chromatograms of all 
deviations from the reference sequence were inspected carefully. If the 
deviation persisted, the PCR and sequencing was repeated to exclude PCR 
errors. All confirmed alterations were analyzed for a potential effect on teneurin-
1 gene expression or amino acid sequence, and were labeled in the alignment 
and summarized (Table 6). 
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exon PCR size fw primer rev primer seq primer
exon 1b) 2845 gagggttagtgcagctagggtac gcacacaagcattctctaatgagaa gagggttagtgcagctagggtac
ttggatattcaaagttgtggc
ccagcactttgggaggccgag
agttaattggtttctaactac
ctttattccatgagctctctc
gaatctgccagatgcatttcc
exon 2 498 gcacagagtcctagctaccatg ggaaggagaacaaagcaaagg cacgtaattactaccaatgg
exon 3a) 237 gcaccactagatgaagggtaaggg cagagaagcagggttccattttg ttgaagtttgaggaattgcag
exon 4 385 ctgaaatcctggtaagtctgtc accatcctctgccaatacttaa gccaagtgggagagtaagtctc
exon 5a) 431 ctgagctccatccagttctcttg ccattcccaccacaagcaaaac cttggctatagcatgattgtttg
exon 6 351 aactcccagttacttggcctaac tcccagctacagttctaatgacc gtgcaaagggatacctggcttg
exon 7 402 ggcaaggccttgaaagacagatg tgttcaacccatcacccttg attttgatatatctgttcttg
exon 8 358 gcaaagaagtaagaaatagggcag tgtctttctagggttgaactgtca gaagttagggatgtttatcag
exon 9a) 346 agcagtaagtgctccacaaacagc ctgttgctgtcaccactactaatg aggtccagagttcctgcaact
exon 10a) 436 ctgtttgtaatcatgaacatgtgcc ttgcatctctactaggagaacag tcaatagagaattgctctttgg
exon 11 420 ggacagagtgtttgcatgagtca ggaaggaacagttagaatttaagag tcaatgtaatctccgtttcatc
exon 12 607 gctagagatctttgtgacatcttg tcccctactccaacctcaaa gcctggttaacccagcaagac
exon 13 187 gcaacagatggtaaaccattagtac catattgtatagctttagtctc gctaccctttctttcttacatgca
exon 14 289 atggttagatgcttccctatagg tagaggctgggctattcctt gcaaatacatcattgttggcc
exon 15 431 gtgaatttaacaaattctgaact gaaatgaacgtggattatgtgg tagaattttctccatttatgta
exon 16 327 cctccccagaatgttattagtagtt cctggctagaagtcagtaattgg gactgttttccaaagtttctac
exon 17 445 acaatacaagtggatatagttgag cactgttgaccactccatgatatta ggaaagggcactgaaattaacc
exon 18 551 taaatgcaatccttaaggttgg tctgttctgtgcatgtaatactgc ctgtttaagctctctcctttgg
exon 19 385 caactctaatcagaattcagtag tgcggtcatctctaagtagtattc gtagccaaagtgatatccacag
exon 20 474 tcactctcaggttctcttatgcc gcttctactggcagtgctttgtc caggccaaagctccttcctgc
exon 21 467 tccatctccttggtacttaagaag gtggcaacagtctcgggattttg ggaagataaatgaattcactc
exon 22 295 tgcctttccattgctatggctt ccatgatgccaaatgacaataatac cagagcttagtgcaaatgtgg
exon 23 628 cactttccgagacatcaccaatg gctcataccaatgtttgcaagtaac ctgtccatggaaagacatggt
exon 24a) 694 aatgattcttgatgcacagagct caacactcagcaattactaaggcat gtctgtggtatgttcatgtaaatgc
exon 25 325 gttaaactgtattagctgccaagtg aaggtggatgttgacataggg attttgcaaagtcctgttatc
exon 26a) 545 cagataggaccacagcaccc cggccattagcatcctcttttg gcttatcccccaaacgtgcctc
exon 27c) 459 ggattcatgattgtcagtgctc tgcaggtcctcaccaagatggac ggattcatgattgtcagtgctc
exon 28 609 atccactagggtttgccacagtg tctatctcacactgtggtcagtaaa ctttagtcgcctcaactttag
exon 29 1442 gcatttgatatcagagatcagtctc caaaggcattgagattctgtga aacactagacctttctgactc
ttctatgaatacgatgctgatg
accttaccaaccccataagag
exon 30 542 gcaacagagtgagactatgtc taccttctcattaattgtgcacg gcaacagagtgagactatgtc
exon 31d) 2406 cactcactgacaaattaaagagag gtggtaacttacaattacacagc tcctttccacaatcaccaag
cctggtgctcatcggtaacac
gttttctagatcagaactctg
tctgtctaccatgcttccctg
caagtaaatcctttccaaccg
tgccttgctttgcgatgacag  
 
Table 3: List of PCR and sequencing primers to analyze the human teneurin-1 
gene. 
31 exons including some flanking sequence were amplified and sequenced. In most 
cases, a separate primer was used for sequencing, but in some intances the PCR forward 
primer was used. For the larger exons (exon 1 including 5’UTR, exon 29 and exon 31 
including 3’UTR), several sequencing primers were used. The PCR size includes the 
flanking region and is therefore larger than the size of the exons alone. Standard PCR 
conditions were used, unless otherwise noted: a) Ta = 60°C, b) ELT buffer 1, c) ELT 
buffer 2, d) ELT buffer 3, te = 3min. 
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4.5 Production of antibodies against human teneurin-4 
 
 RT-PCR was performed on human brain RNA using the Superscript RT-
PCR kit (Invitrogen) and oligodT primers. The obtained cDNA was subsequently 
used as a template for PCR amplification of human teneurin-4 sequences. 
 
4.5.1 ICD antibody 
  
 A recombinant protein corresponding to the first exons of human 
teneurin-4 was produced using the same strategy as described in 2.1.1 and 
purified from bacterial lysates using the HIS-tag. Primers used for cloning were 
hten4 fw SphI: ACTAGCATGCTATCCATATGACGTCCCAGAC and hten4 rev KpnI: 
TAGTGGTACCTGTGCGGCAGAATTCCTCGGC. The resulting PCR fragment was 
cloned SphI and KpnI into pQE30 for production of recombinant protein in 
bacteria. In addition to the generation of polyclonal antibodies, the purified 
protein was also submitted for the generation of monoclonal antibodies to the 
FMI monoclonal antibody facility. 
 
 
4.5.2 ECD antibody 
 
 A recombinant fusion protein between the Tenascin-C signal peptide and 
the human teneurin-4 EGF-like repeats was generated using the same strategy 
as described in 2.1.2. The following primers were used:  
TNC/hten4 EGF fw: CGGCAGACTGGGCTCAATGAGTCGGTGGATAACTGC,  
TNC/hten4 EGF rev: GCAGTTATCCACCGACTCATTGAGCCCAGTCTCCCG and 
hten4 EGF rev: TAGTGCGGCCGCTTAGTGATGGTGATGGTGATGATCATTGTCTTTGC 
TGTCACC containing a HIS tag and NotI site. The resulting PCR fragment was 
cloned using HindIII and NotI, sequenced and transfected into 293T EBNA cells 
to test expression and secretion and finally to produce the recombinant protein. 
In addition to the generation of polyclonal antibodies, the purified protein was 
also submitted for the generation of monoclonal antibodies to the FMI 
monoclonal antibody facility. 
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4.6 WB analysis of brain tumors 
 
 Protein lysates were prepared from pieces of frozen tumor material that 
was obtained from the Merlo lab at the University hospital, Basel. RIPA-buffer 
was added to the tumor pieces and they were homogenized by using a small 
pestle. The lysates were clarified by centrifugation and the protein concentration 
determined by a Bradford Assay. Normal brain protein samples were purchased 
from BioChain, including one sample of total brain (P1234035, age 71 Lot No 
A908046), cerebral cortex (P1234042, age 77, Lot No B107064) and cerebellum 
(P1234040, age 66, Lot No B109120). The samples were analyzed on a 7.5% 
Polyacrylamid-gel, blotted for 2h using a semi-dry system and stained with 
amidoblack to verify the amount of protein on the membrane. HRP-labeled 
secondary antibody was used at a dilution of 1:10’000 and the signal detected 
by Super Signal. As a loading control, β-actin or vinculin antibodies were used. 
 
 
4.7 IHC of brain tumors 
 
 Frozen sections of brain tumors were obtained by the Merlo lab at the 
University Hospital, Basel. The sections were stained with the Ventana 
Automated Staining module using the standard IHC protocol with the following 
parameters: No pretreatment, 4 min AB-block, primary antibody incubation 60 
min, secondary anti-rabbit incubation 32 min, Hematoxylin counterstain. Both 
hten4 ECDA and hten4 ECDB antibodies were used 1:1000 and resulted in 
similar staining, and subsequently only hten4 ECDA was used. A control using 
the preimmune serum was performed in parallel, and if enough sections were 
available also H&E staining. H&E Staining Procedure: Thaw 20’ at RT, 30’’ dH2O, 
1 x 2’ Hematoxylin, rinse dH2O, 5’ tap water, 12 x dip in acid ethanol, 2 x 1’ tap 
water, 2’ H2O, 30’ Eosin, 2 x 2’’ 95% EtOH, 2 x 2’’ 100% EtOH, 2 x 5’ 
Histoclear. Stained sections were coverslipped usind the Histoclear kit, dried for 
at least 30 min and viewed on an Olympus Eclipse E600 microscope. Images 
were acquired using the Image Access software.  
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4.8  Microarray analysis of brain tumors (performed in the 
 Hemmings lab) 
 
Total RNA was extracted from the primary tumor samples using Trizol reagent, 
according to manufacturer's instructions, and resuspended in 
diethylpyrocarbonate (DEPC) treated water. Total RNA was further purified using 
the RNeasy kit and following the protocol for Total RNA cleanup. RNA was then 
amplified and labelled using the Affymetrix 2-cycle amplification protocol as per 
manufacturer's instructions (Affymetrix). Samples were hybridized to Affymetrix 
U133v2.0 GeneChips and scanned using an Affymetrix GeneChip scanner as per 
manufacturer's instructions. Expression values were estimated using the GC-
RMA implementation found in Genedata's Refiner 4.1 (Genedata, Basel, 
Switzerland) package. Data-mining and visualization was performed using 
Genedata's Analyst 4.1 package. All samples were quantile normalized and 
median scaled to correct for minor variations in their expression distributions.
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5. RESULTS 
 
 
 
Part I – Teneurins in Development 
 
 
 
5.1  Teneurin-1 is expressed in interconnected regions 
of the developing brain and is processed in vivo. 
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5.2 Expression of Teneurin-4 in the developing chick 
 embryo 
 
 
5.2.1 Expression of teneurin-4 in the visual system 
 
 As it is the case for the other teneurins examined so far, teneurin-4 was 
prominently expressed in the developing visual system. At E4, strong staining of 
primary fibers of the lens was observed, particularly towards the posterior side 
(Figure 12 A). The expression of teneurin-4 in the lens was transient and 
weaker in the lens of older embryos (Figure 12 B). At E7 teneurin-4 
immunolabeling was found in the ciliary body and ciliary marginal zone of the 
retina (Figure 12 B) As it is known for teneurin-1 and -2, teneurin-4 was present 
along the retinotectal pathway: In the E12 retina, teneurin-4 was found in the 
IPL where synaptic connections between amacrine cells, bipolar cells and RGC’s 
are formed, and in the OFL where the RGC axons travel to the optic nerve 
(Figure 12 C). Teneurin-4 was present in the optic nerve, particularly after 
crossing the optic chiasm (Figure 12 D) where strongly labeled axon tracts 
running along the dorsal thalamus to the OT were observed (Figure 12 E). In 
the OT, the stratum opticum in which the RGC axons run on the surface of the 
OT until they reach the appropriate target region was strongly stained. In 
addition, the stratum griseum et fibrosum superficiale (SGFS) of the OT was 
teneurin-4 positive (Figure 12 F). At E17, teneurin-4 expression in the visual 
system remained similar, but the RGC axons in the retina were much more 
strongly stained (Figure 12 G). Additionally, the ICD antibody revealed staining 
of neurons in the INL. In the optic tectum neurons strongly expressed teneurin-
4 (Figure 12 H). 
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Figure 12: Teneurin-4 expression in the visual system. 
A: E4 lens and retina (ICD); B: E12 lens and retina (ICD); C: E12 retina (ECD); D: E12 
optic chiasm (ECD); E: E12 optic fiber tract running along dorsal thalamus (ECD); F: E12 
optic tectum (ECD); G: E17 retina (ICD); H: E17 neurons in the optic tectum (ECD). The 
domain of teneurin-4 recognized by the antibody is indicated in parentheses. Legend: cb 
= ciliary body, cm = ciliary margin, dt = dorsal thalamus, epl = external plexiform layer, 
gcl = ganglion cell layer, inl = inner nuclear layer, ipl = inner plexiform layer, l = lens, oc 
= optic chiasm, ofl = optic fiber layer, oft = optic fiber tract, onl = outer nuclear layer, ot 
= optic tectum, ret = retina, sgfsf = stratum griseum et fibrosum superficiale.  
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5.2.2 Expression of teneurin-4 in the central nervous sytem (outside of 
visual system) 
 
 In E4 chick embryos, both antibodies detected teneurin-4 in the ventral 
horn of the spinal cord (Figure 13 A), and staining was also observed in the 
efferent motor axons exiting the ventral root (Figure 13 B). In the E12 olfactory 
system, Teneurin-4 was present in the olfactory epithelium (Figure 13 C), in 
mitral cells of the olfactory bulb (Figure 13 D) and in the piriform cortex which 
receives input from the mitral cells (Figure 13 E-H). In the piriform cortex, it 
was particularly evident that the ICD antibody stained the cell bodies (Figure 13 
E, G), whereas the ECD antibody labeled the ECM surrounding the cells (Figure 
13 F, H). The distribution of the teneurin-4 ECD staining around cells rather 
than on the cell surface may be explained by ECD shedding which releases the 
ECD from the cell membrane. At high magnification, the ICD antibody staining 
showed that only a subset of neurons in the piriform cortex expressed teneurin-
4, whereas others did not (Figure 13 G). 
 
 
 
Figure 13: Teneurin-4 expression in the the CNS (outside of visual system). 
A: E4 spinal cord (ECD); B: E4 ventral root nerves (ECD); C: olfactory epithelium (ECD), 
D: E12 olfactory bulb (ICD); F: E12 piriform cortex (ICD); F: E12 piriform cortex (ECD); 
G: piriform cortex (ICD); H: E17 near habenual nuclei (ECD). The domain of teneurin-4 
recognized by the antibody is indicated in parentheses. Legend: cPi = cortex piriformis, 
gcl = granule celll layer, mcl = mitral cell layer, oe = olfactory epithelium, vh = ventral 
horn, vr = ventral root. Arrows = teneurin-4 positive cells in the cPi, arrowheads = 
teneurin-4 negative cells in the cPi. 
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5.2.3 Expression of teneurin-4 in non-neuronal tissues 
 
 Expression of teneurin-4 in non-neuronal tissues was particularly evident 
in young embryos. At E4, strong staining was observed in the mesenchyme 
around the lung primordium with both ICD and ECD antibodies (Figure 14 A). 
Teneurin-4 was also expressed in other developing organs, such as in tubules of 
the mesonephros (Figure 14 A, B) and in the gut epithelium as well as in the 
surrounding mesenchyme (Figure 14 C). At E7, no staining in these organs was 
detected anymore, suggesting that the expression of teneurin-4 in the 
developing lung, kidney and gut is transient. Other sites of teneurin-4 
expression included the mesenchyme at various sites, for example in the 
pharyngeal arches, where teneurin-4 was present in the mesenchyme and in the 
ectoderm as previously found by whole-mount in-situ hybridization133.  
 
 
Figure 14: Teneurin-4 expression in non-neuronal tissues. 
A: E4 lung and kidney (ECD); B: E4 kidney (ICD); C: E4 gut (ICD). The domain of 
teneurin-4 recognized by the antibody is indicated in parentheses. Legend: ge = gut 
epithelium, m = mesenchyme, lm = lung mesenchyme, lp = lung primordium, mn = 
mesonephros. 
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5.2.4 Expression of teneurin-4 in the limb 
 
Outside the CNS, the most intriguing teneurin expression patterns were 
found in the developing limb. They suggest an important role in pattern 
formation, and as in the developing brain, the pattern for each teneurin in the 
limb is distinct and complementary. Teneurin-4 was present in the two most 
important signaling centers of the developing limb, in the AER, which regulates 
distal outgrowth, and in the ZPA, which regulates anterior-posterior patterning 
(Figure 15 A). Staining of the AER and adjacent ectoderm was observed at E4 
(Figure 15 B) and E5 (Figure 15 G). However, expression of teneurin-4 at the tip 
of the limb appeared to be dynamic and involve both the AER as well as the 
underlying mesenchyme (Figure 15 C, I). Potentially, teneurin-4 is expressed by 
the AER and the ECD is shed and distributes to the underlying mesenchyme. 
Teneurin-4 expression at the tip of the limb persists to E6 (Figure 15 I). 
Particularly with the ICD antibody, teneurin-4 was detected in the ectoderm 
enveloping the mesenchyme of the limb (Figure 15 D, F). As with the ECD 
antibody, the ectoderm was stained and the staining extended to the underlying 
mesenchyme in regions between mesenchyme undergoing chondrogenic 
differentiation (Figure 15 K). The strongest teneurin-4 expression was detected 
in the ZPA, as described previously with in situ hybridization133. This signal 
persisted from E4 (Figure 15 E) to E5 (Figure 15 H) and E6 (Figure 15 J). In 
older limbs (E7) some residual teneurin-4 expression in the ectoderm and 
underlying mesenchyme was observed (Figure 15 L) but the strong staining in 
the AER and ZPA was gone, indicating that teneurin-4 expression is transient 
and dynamic during limb development. In comparison, teneurin-1 is expressed 
in the dorsal ectoderm and ventral mesoderm (unpublished observation) and 
teneurin-2 is highly expressed exclusively in the AER117. Thus, teneurin-4 is 
unique in that it is expressed in both crucial signaling centers of the developing 
limb, which is not the case for any other teneurin. 
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Figure 15: Teneurin-4 expression in the developing limb. 
A: E4 limb primordium (ECD); B: E4 limb tip showing labeling in the AER (ECD); C: E4 
limb tip showing immunostaining in the mesenchyme underlying the AER (ECD); D: E4 
limb tip (ICD); E: E4 limb ZPA (ECD); F: E4 limb dorsal mesenchyme (ICD); G: E5 limb 
(ECD); H: E5 limb ZPA (ECD); I: E5 limb tip (ECD); J: E6 limb ZPA (ECD); K: E6 limb 
(ECD); L: E7 limb (ECD). The domain of teneurin-4 recognized by the antibody is 
indicated in parentheses. Legend: AER = apical ectodermal ridge, dm = dorsal 
mesenchyme, e = epithelium, m = mesenchyme, vm = ventral mesenchyme, ZPA = 
zone of polarizing activity. 
 
 
5.2.5  WB analysis of teneurin-4 expression during chick development 
 
Protein lysates of limb buds and different regions of the brain were 
collected at specific developmental stages and analyzed by WB using both ICD 
and ECD antibodies (Figure 16). Whereas full-length teneurin-4 was detected 
with both antibodies, N-terminal processing products were observed with the 
ICD antibody suggesting that teneurin-4 is processed by ECD shedding, possibly 
followed by RIP. Teneurin-4 expression was particularly strong in the retina, 
where a distinct pattern of N-terminal processing products was observed. The 
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same was observed before for teneurin-1 (unpublished overvations) and 
indicates that teneurins are differentially processed in the retina compared to 
other tissues. Both antibodies showed stronger expression in young embryos 
(E4 and E7), which decreased in the E12 brain and was very weak in the E17 
brain. In the early embryo, teneurin-4 expression in the limb bud is as strong as 
in the retina and the brain. In E12 and E17 brains, teneurin-4 was more highly 
expressed in the forebrain and the retina and only at low levels in the optic 
tectum and the cerebellum. 
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Figure 16: WB analysis of teneurin-4 expression during chick development. 
Protein lysates from different tissues and developmental stages were analyzed using the 
ICD and ECD antibody. Full-length teneurin-4 was observed using both antibodies, and 
N-terminal processing products with the ICD antibody only. Teneurin-4 was more 
strongly expressed in younger embryos (E4 and E7), and expression decreases in the 
brain of older embryos (E12, E17). β-actin was used as a loading control. 
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Part II – Teneurins in Disease 
 
5.3 Teneurin-1 as an XLMR candidate gene 
 
 
5.3.1 Analysis of the human teneurin-1 genomic locus 
 
 The human teneurin-1 gene (called odz-1, gi:110347399) was analyzed 
using the UCSC browser. The exons to be sequenced were defined based on the 
transcript NM_014253. A list of the 31 sequenced exons including the sizes of 
the exons and preceding introns is provided in Table 4. 
 
exon exon size intron size 5'flanking 5'end 3'end 3'flanking
exon 1 281 tccctttctcttccag gactgcttgcattaaa aaaaatctactcaag gtatgtttttattgga
exon 2 261 67295 ctttgtttcttctcag agatggaattctgtga tctgatggggaaaatg gtaataaactacttga
exon 3 57 1628 atgtttactgttacag gtttcaaattctctcc gctgggtctactcaag gcaagtgttttcaaat
exon 4 241 157097 cttctctcctctttag atgtgcagagcagccc taccattggagaccag gtacttgagctattat
exon 5 239 31705 tgtttccttttcacag gcatttcctgttcaaa ctagcctatgtgattg gtaagtcctttttgtc
exon 6 153 33177 gcttgttctcttgcag cagtgcatttgttcgg aaatcagagaaaaaag gtacagtgatcaaaat
exon 7 206 17899 ctacctttaaaactag tgtttcagaagggac acatactcaggtattt gatattataggtattt
exon 8 211 1453 tttgtatttgttccag tttgattttgtaaaac ttaactacagcaattg gtaagctgctttgcct
exon 9 102 5103 ttctctgtattactag aaataatggatgactg cctgactgtgctagag gtaatgttgctctgtt
exon 10 195 1271 atttgccaaccttcag attcctgccctgtgct gaaatatgcgaggaag gtcagaatcccatttt
exon 11 201 3151 ttttttgtgccttcag aggactgcctagaccc tctgactgctcaacag gtgtagtggagttaat
exon 12 186 76230 tttgaattccccacag agctgtgtaccatgga gaccactgcacaattg gtaagtaccaccatac
exon 13 25 1601 tttcccctccctttta gctcactacttagatg ttagatgctgtccgag gtaagatttttctcac
exon 14 147 1931 tctgatgtcttttcag atggctgcccagggct ttggacaatgatggag gtgagtcatttataaa
exon 15 217 14580 tgggttttatttccag atggtttaaccgactg tgtcatttgacagcag gtacatatgtatttat
exon 16 120 16890 tggtcttgtgttgcag gcgtgcctgtgtgatt gccggcaagatggaag gtatgtcaatgttgtt
exon 17 262 6238 tgtttttccttcttag ctttgacctcgtggcc tgttcctgagctgcag gtgagtatattggcct
exon 18 268 2579 tttttttttatttcag gttgtacaggaggaaa ctggcagaggctttgg gtatgttgaactaatt
exon 19 144 16813 aactctttgtttgcag tatctgtgggatatga ttgaatcctcaaagtg gtaagtagctttttaa
exon 20 250 6294 ttttccttgaatctag gaatcatacataaagg gtattttggaattaag gtaagtcttctctaat
exon 21 233 15051 cttttctcttccttag cacaagtcctgctcac ctgaatagccctcgag gtaaaaaataaataaa
exon 22 155 28240 tgctctttcccaacag gcatcacagttgatag aatggacatcactcag gtaggcatcactggtt
exon 23 367 30698 tctgttcgtttcacag gtgcgattagagtggc tgtgactgtttttcag gtatgacctttttagc
exon 24 511 1450 agtctttctcccacag gtgatggtggctatgc ggacaaccgtttatga gtaagtttctaattct
exon 25 173 13821 tggttacattcctcag gtatgaccccgaggga tatattttaaaacaag gtaagattgtttccaa
exon 26 236 1050 gctcttctgtctacag aaaatactcaaagtac tgaaaggaggctgagg gtaaggcttgacttta
exon 27 297 12682 tatctctttctcatag gcccacaacagaaacc tacctacttagaaaaa gtaagtacatagggga
exon 28 388 5987 ctttgtctcgtttcag tctgtgatgcttctcc agatacaggcaaacag gtttgttgtgaaagag
exon 29 1221 822 gttttggttcctgcag gacctcttattggacg gcaaagtataccacag gtatttaaactattta
exon 30 143 821 atattgtgtctcacag acatcagaagttggtt gtgggatcctggaaag gttagtaaaagtttta
exon 31 3319 1378 ctctctttcctagact atcctgggcattcagt actactaatcagtagt aaatcgaagagaaaca  
 
Table 4: Exons to be sequenced. 
The human odz1/teneurin-1 gene contains 31 exons which were sequenced. The size of 
the exon, the size of the preceding exon and the 5’ and 3’ splice junctions are listed. The 
coding sequence is written in bold, the adjacent noncoding sequence in normal script. 
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5.3.2 Summary of SNPs in the analyzed sequence 
 
 In the entire genomic locus of the teneurin-1 gene spanning more than 
600kb, 1929 single nucleotide polymorphisms (SNPs) are present according to 
the Entrez SNP database which displays SNPs based on the dbSNP build 129. To 
know which alterations can be expected after sequencing of patient DNAs, a list 
of SNPs found in the teneurin-1 coding sequence including the exon flanking, 5’ 
upstream and 3’ untranslated regions that were included in my study was 
composed (Table 5). In the genomic region to be sequenced, 38 known SNPs 
are present: 27 SNPs are located in non-coding regions (5’ upstream, exon 
flanking, 3’ untranslated), and 11 in the coding sequence, of which 6 are 
synonymous and 5 result in amino acid exchanges. SNP rs36065191 results in 
the exchange of a tyrosine with a histidine in exon 1, SNP rs2213591 in an 
exchange of a methionine with a threonine in exon 6, and two SNPs in exon 11 
lead to the replacement of a methionine with a valine (rs16999334) and a lysine 
with a glycine (rs6649271), respectively. One polymorphism in exon 23 
(rs35405207) inserts a G nucleotide and thus results in a frameshift, however it 
is lacking validation by the HapMap project, multiple and independent 
submissions or frequency and genotype data. However, of these SNPs affecting 
the teneurin-1 amino acid sequence, only the one in exon 6 (SNP rs2213591) 
was found in my patients and controls, which included 24 individuals in total. 
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SNP sequence location aa change
rs5956718 ttggtcttgcctttgaaaggtatcca[C/G]aatccaaccagatctcttcaatttc 5'upstream
rs58984127 TATGAACATATACATATATATATATA[C/T]ACACACACCAATGATTCAACAACAA 5'upstream
rs3834690 CTGATTTTTTAAAAAAGGCTTACACA[-/CA]TTTGACTGATATATGTTTTAAATGG 5'upstream
rs5956717 cgcccggccTATGTAGGCTGATTTTT[A/T]AAAAAAGGCTTACACATTTGACTGA 5'upstream
rs5956716 gttagccaggatggtctcgatctcct[C/G]acctcgtgatccacccgcctcggcc 5'upstream
rs11310365 TGTAGGCTGATTTTTATTGATCAATT[-/T]GATTGATTGATTGATTGATTGATTT 5'upstream
rs11284309 GATGTAGGCTGATTTTTATTGATCAA[-/T]TTGATTGATTGATTGATTGATTGAT 5'upstream
rs10284039 TTTCATTCTTTACATTATTTTGTCAT[C/T]ACCATTTCAGTCCACTGTTGCAACT 5'upstream
rs34734884 AAATAGAGGACAACGTTGTTCTATGG[-/G]TGTGTGCGTGTTTTTAATGTTAAAA 5'upstream
rs57545535 GGAGAGAAGTAAAAGACAAACTAGAT[A/G]ACATGAAGCTAGCCGGAGGCAATAA 5'upstream
rs5958635 AGATTCACAATTGGTCCTGATAATAC[C/T]ATCAAAGGAGAGAAGTAAAAGACAA 5'upstream
rs36065191 AAGATGGAAGAAAACCAAGACAGTCA[C/T]ACAACTCCAGGGAGACCCTGCACGA exon 1 coding TAC (Y) g CAC (H)
rs5958616 TCTAGCTGGTAGCCATGCCGAGAAAC[A/G]CTGTGCATGTCTGTTTGGTAGCCAG exon 2 coding AGC (S) ? AGT (S)
rs34981391 CTAGAGATGGGATCTGATGTGGACAC[A/G]GAGACAGAAGGTGCTGCCTCACCTG exon 2 coding ACA (T) ? ACG (T)
rs16994522 GGAAACACAAGTTTGGGCTATAAAAA[C/G]CAAAGCCAGTTGCTACAAAAACACA exon 5 5' flanking
rs2213591 CAAAGGGAACAGGGGGACCGAGTCCA[C/T]GGACACTACTTACTCTCCAATTGGA exon 6 coding ATG (M) g ACG (T)
rs34322253 CCCACCACACAGCACAGGGCAGGAAT[C/T]TGAAGGTTGGCAAATGAACTTGTAA exon 10 5'flanking
rs60027201 GTGAACAGGTATGGCCAACATACCTT[A/G]GTATGATGAAACGGAGATTACATTG exon 11 5'flanking
rs16999334 TACACAGATGCCATGGTTGGAACACA[C/T]TGGGTCTAGGCAGTCCTCTGAAGGC exon 11 coding ATG (M) g GTG (V)
rs6649271 GCCAGTAGAACAGTGACATTCTCCTT[C/T]TACACAGATGCCATGGTTGGAACAC exon 11 coding AAA (K) g GAA (G)
rs7882953 ATTCGATCATAAAAAAGTCTTGAAGT[A/G]TGCTGAGAGAAGAGAGTTTGGCTTT exon 15 coding AGC (S) ? AGT (S)
rs5958502 ACCCAAGGGtatatatatatatatat[A/T]tatttatttatTTTTTACCTCGAGG exon 21 3'flanking
rs61310498 ACCCAAGGGTATATATATATATATAT[-/ATATAT]TTATTTATTTATTTTTTACCTCGAG exon 21 3'flanking
rs34974707 TCTTTAGATGACCCAAGGGTATATAT[-/TATATA]ATATATATATTTATTTATTTATTTT exon 21 3'flanking
rs10673684 ATCTTTAGATGACCCAAGGGtatata[-/TATATA]tatatatatatttatttatttattt exon 21 3'flanking
rs10656532 AATAAAATCTTTAGATGACCCAAGGG[-/TATATA]tatatatatatatatatttatttat exon 21 3'flanking
  
rs35405207 AATTGTCCATAGGATTTACTGCAAGG[-/G]TCTGTTGGCCACTCTAATCGCACCT exon 23 coding GAC (H) ? frameshift!
rs12013090 GCTAAGGAGGAAGGGGCTTTCATCTT[C/T]GCATCTTTGGCATAGCCACCATCAC exon 24 coding GCA (A) ? GCG (A)
rs960869 ACCTCTCCAGTGGGAAACGTTGCATT[G/T]GTCAGGTGTCCCTCGGGGTCATACC exon 25 coding ACC (T) ? ACA (T)
rs59812568 GGAAGGGAAGAGCAGGAAGCAGAAAA[C/G]AGACAGGTTTAGTTTTAGGAGGCAC exon 26 5'flanking
rs34194370 ACAAACAAACAAACAAACAAACAAAC[-/AAAC]AAAACACCTATAAAAGTTCTATATC exon 26 3'flanking
rs2076165 TGAATAAACGTCACCAATCCCGAAGG[C/T]GAATATGTGATGTTCACTTCATTAT exon 27 coding TCA (S) ? TCG (S)
rs41312759 ACAGTTAAGGATGAAACTGCTTCTCA[C/T]AATAGAGATAGAGAACCTTGGGTTC 3'untranslated
rs6648597 TATTGCACCACCTATTCAAATAGCCC[A/G]TAAGTTCTGCCAACAGTTAAGGATG 3'untranslated
rs59761033 AGTTTCAGATACTATTGCACCACCTA[A/G]ACAGTTAAGGATGAAACTGCTTCTC 3'untranslated
rs41310478 TTTGGTATCATGTACACACGAGCAAA[C/T]AGCGGCTATACAGTCTGGTTACCAC 3'untranslated
rs5958477 GTTCAATACAGAATTGTACATTTGAA[A/G]GATAAATCTAAGTGGGCTGAAACAA 3'untranslated
rs5958476 CGATTAAATAAAGATAAATGGGTAAG[G/T]ACGGAGAACGAAAATAACTAACTGT 3'untranslated  
 
Table 5: List of SNPs in the odz coding and exon flanking region. 
The names and sequences of all SNPs present in the analyzed regions of the teneurin-1 
locus are listed, indicating whether they are located in a coding or non-coding region of 
the gene. The last column lists the consequences of SNPs located in the coding regions 
on the amino acid sequence of the teneurin-1 protein. Sequence in lower case is used for 
sequence identified by RepeatMasker as low-complexity or repetitive elements. 
SNPs in the coding region are bold, and non-synonymous SNPs are marked in red.  
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5.3.2 Summary of XLMR patient sequencing results 
 
 The coding, exon flanking, 5’ upstream and 3’ untranslated regions of the 
human teneurin-1 gene were sequenced in 21 XLMR patients linked to Xq25 and 
compared to the reference sequence. The results are summarized in Table 6. In 
total, 27 alterations were identified, 21 SNPs in the non-coding regions (5’ 
upstream, exon flanking, 3’ untranslated), and 6 in the coding sequence. 16 of 
these alterations were known SNPs, and 11 were novel and may represent novel 
SNPs or spontaneous mutations. In particular the nucleotide changes in the 
flanking region of exon 18, exon 20 and exon 26 may constitute novel SNPs, 
since they were found in several patients.  
 
 Generally, the 50 intronic nucleotides adjacent to the splice site are 
thought to be important for the regulation of splicing, therefore it is difficult to 
predict if a nucleotide alteration in the exon flanking region has an effect on 
splicing. Only the nucleotides immediately adjacent to the splice site are highly 
conserved, and none of the alterations I have found interferes with these 
splicing recognition sites. Of the 6 alterations found in the exons, 5 were 
synonymous, and only one located in exon 6 resulted in an amino acid sequence 
change. However, since this alteration corresponded to a known SNP 
(rs2213591) and was found in two different XLMR patients, it is very unlikely to 
be the cause for the disease. One alteration found in exon 29 was novel, but it 
is a synonymous mutation and therefore not likely to affect the function of the 
teneurin-1 protein.  
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SNP (if known) patients region nucleotid chanamino acid change
rs5956718 p 5’ upstream C ? G
? (near rs58984127) p 5’ upstream Δ TA
rs5956717 TW, MD, GL, a, b, f, g, m, n, o, p   5’ upstream A ? T
? p 5’ upstream C ? T
rs5956716 n 5’ upstream G ? C
? n 5’ upstream A ? T
rs11284309, rs11310365 n, p 5’ upstream TCA insert
rs10284039 p 5’ upstream G ? A
rs5958635 n, p 5’ upstream G ? A
rs5958616 n exon 2 coding C ? T AGC (S) ? AGT (S)
rs16994522 g exon 5 flanking 5' C ? G
rs2213591 g, p exon 6 coding T ? C ATG (M) ? ACG (T)
? MD, m, n, s exon 18 flanking 5' Δ T
? j, q, r, t, v, w exon 20 flanking 3' G ? T
rs5958502, rs61310498 l exon 21 flanking 3' A ? T
rs34974707, rs10673684, MD, a,b,c,d,h,I,j,k,l,m,n,o,p,q,r,s,t, v exon 21 flanking 3' TA insert
rs10656532
? n exon 23 flanking 5' C ? A
rs12013090 a, h, r exon 24 coding A ? G GCA (A) ? GCG (A)
? u exon 24 flanking 3' A ? G
? d exon 24 flanking 3' G ? A
rs960869 TW, c, f, I, j, k, n, q exon 25 coding C ? A ACC (T) ? ACA (T)
? (near rs34194370) MD, g, l, o, p, t exon 26 flanking 3' Δ/insert GTT
rs2076165 c, f, j exon 27 coding A ? G TCA (S) ? TCG (S)
? w exon 29 flanking 5' T ? G
? c exon 29 coding T ? G GTT (V) ? GTG (V)
rs41312759 w 3’untranslated C ? T
? MD 3’untranslated A ? C
rs6648597 b, c, j, k, t, w 3’untranslated C ? T
rs5958476 ref, g, v, w 3’untranslated C ? A  
 
Table 6: List of SNPs and unknown alterations found in XLMR patients. 
All alterations found in 23 XLMR patients and 3 controls are listed, indicating whether 
they correspond to a known SNP (black) or if they do not represent known SNPs (red). 
The location of the alteration within the gene, nucleotides exchanged, and consequences 
on the amino acid sequence are indicated. The last column lists the patients for which the 
alteration was found. 
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5.3.3 SNPs in the 5’ upstream region 
 
 Remarkably, patient p was found to have several alterations in the 5’ 
upstream region, where the promoter of teneurin-1 may be located. 5 of these 
alterations corresponded to known polymorphisms, and 2 were novel. Whereas 
it is unlikely that one SNP in the 5’ upstream region of teneurin-1 causes a 
XLMR phenotype, possibly the accumulation of several SNPs may result in XLMR 
caused by altered teneurin-1 expression. Therefore, two additional samples of 
affected brothers of the same XLMR families were obtained to test whether they 
also exhibit the same SNPs. The results are summarized in Table 7. It can be 
ruled out that the accumulation of SNPs in the 5’upstream region is responsible 
for the XLMR phenotype of patient p, because 6 of the 7 SNPs were not shared 
by patient p and his affected brothers. The remaining SNP that both patient p 
and the brothers carry is very common and was found in most patients and the 
healthy controls, and is thus unlikely to result in XLMR. 
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rs5956718 
reference      agatctggttggattctggatacctttcaaa
patient_p       agatctggttggattgtggatacctttcaaa
p_brother1     agatctggttggattctggatacctttcaaa
p_brother2  agatctggttggattctggatacctttcaaa
? (near rs58984127)
reference      gtgtatatatatatatatgtatatgttcatat
patient_p       gtgtatatatatata--tgtatatgttcatat
p_brother1     gtgtatatatatatatatgtatatgttcatat
p_brother2 gtgtatatatatatatatgtatatgttcatat
rs5956717
reference      tgtaagccttttttaaaaaatcagcctacat
patient_p       tgtaagcctttttttaaaaatcagcctacat
p_brother1     tgtaagcctttttttaaaaatcagcctacat
p_brother2 tgtaagcctttttttaaaaatcagcctacat
?
reference      tttgggaggccgaggcgggtggatcacgagg
patient_p       tttgggaggccgaggtgggtggatcacgagg
p_brother1     tttgggaggccgaggcgggtggatcacgagg
p_brother2 tttgggaggccgaggcgggtggatcacgagg
rs11284309, rs11310365
reference      tcaatcaatcaatca---aattgatcaataaaa
patient_p       tcaatcaatcaatcatcaaattgatcaataaaa
p_brother1     tcaatcaatcaatca---aattgatcaataaaa
p_brother2 tcaatcaatcaatca---aattgatcaataaaa
rs10284039
reference      gtggactgaaatggtgatgacaaaataatgt
patient_p       gtggactgaaatggtaatgacaaaataatgt
p_brother1     gtggactgaaatggtgatgacaaaataatgt
p_brother2 gtggactgaaatggtgatgacaaaataatgt
rs5958635 
reference      cttctctcctttgatggtattatcaggacca
patient_p       cttctctcctttgatagtattatcaggacca
p_brother1     cttctctcctttgatggtattatcaggacca
p_brother2 cttctctcctttgatggtattatcaggacca  
 
Table 7: 5’ upstream polymorphisms in patient p. 
The SNPs (black) and unknown alterations (red) found in patient p are listed, and the 
sequence of the reference is compared with patient p and two affected brothers in patient 
p. The altered nucleotide was shown in bold and red. 
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5.4 Teneurin-4 overexpression in brain tumors 
 
 
5.4.1 Microarray data of brain tumors 
 
 From a microarray analysis performed in the Hemmings lab, teneurin 
expression data of normal adult human brain and a panel of different types of 
brain tumors, including astrocytoma, oligodendroglioma, glioblastoma and 
secondary glioblastoma were obtained. Teneurin-2 (215993_at, 231867_at) and 
teneurin-3 (219523_s_at) did not show any difference in expression levels 
between normal brain and brain tumors, and the values of teneurin-1 
expression were too low to be considered. In contrast, teneurin-4 (213273_at) 
was strongly and consistently upregulated in all types of brain tumors, 13.7-fold 
in astrocytoma, 6.3-fold in oligodendroglioma, 8.7-fold in glioblastoma and 6.4-
fold in secondary glioblastoma (Figure 17). 
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Figure 17: Teneurin-4 expression in normal brain and brain tumors. 
The average expression levels of teneurin-4 in human normal brain (n = 2), astrocytoma 
(n = 8), oligodendroglioma (n = 7), glioblastoma (n = 13) and secondary glioblastoma (n 
= 3) including error bars indicating the standard deviation. 
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Figure 18 depicts the expression values of the individual samples, which 
show that the upregulation of teneurin-4 was very consistent in all tumor 
samples, with a two-fold upregulation even present in brain tumors with low 
teneurin-4 expression. The highest expression values were observed in 
astrocytomas, some of which had up to 18.8-fold upregulation of teneurin-4. 
Astrocytomas had two-fold higher teneurin-4 expression levels than 
oligodendrogliomas, while glioblastomas ranged in between. The sample number 
of secondary glioblastoma (n = 3) was too small to conclude that teneurin-4 
expression is lower in secondary glioblastoma than glioblastoma. The expression 
values of all samples are depicted in Figure 18 and listed in Table 8. 
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Figure 18: Teneurin-4 expression in individual normal brain and tumor samples. 
The expression levels of teneurin-4 in human normal brain (n = 2), astrocytoma (n = 8), 
oligodendroglioma (n = 7), glioblastoma (n = 13) and secondary glioblastoma (n = 3). 
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brain (n = 2) 16 67.68 
average: 31.08 17 253.94 
SD: 9.17 glioblastoma (n = 12) 
1 24.59 average: 277.56 
2 37.57 SD: 126.76 
astrocytoma (n = 8) 18 167.47 
average: 425.66 19 360.73 
SD: 162.57 20 164.78 
3 586.54 21 474.24 
4 218.12 22 134.24 
5 511.68 23 397.96 
6 292.94 24 394.07 
7 211.62 25 82.38 
8 547.85 26 402.95 
9 437.22 27 218.22 
10 599.29 28 275.25 
oligodendroglioma (n = 7) 29 258.46 
average: 200.12 secondary glioblastoma (n =3) 
SD: 76.29 average: 197.71 
11 223.98 SD: 86.86 
12 305.32 30 131.28 
13 190.22 31 296.01 
14 148.79 32 165.84 
15 210.88   
 
Table 8: List of teneurin-4 expression values.  
The expression values of each individual normal brain and brain tumor sample are listed. 
Samples of 2 normal brains, 8 astrocytomas, 7 oligodendrogliomas, 12 glioblastomas and 
3 secondary glioblastomas were analyzed. For each group, the average and standard 
deviation (SD) was calculated.  
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5.4.2 WB analysis of brain tumors 
 
To be able to analyze teneurin-4 expression on protein level, antibodies 
against human teneurin-4 were produced. It was attempted to obtain antibodies 
against both the ICD and ECD to be able to confirm results with several 
independent antibodies and to study teneurin processing and signaling. Both 
antigens were used for the production of polyclonal as well as monoclonal 
antibodies. Polyclonal antibodies were successfully obtained in both rabbits A 
and B for the ECD antigen, but none of the rabbits for the ICD antibodies 
generated antibodies, probably because the size of the antigen was too small to 
be immunogenic (<10 kDa). Screening of monoclonal antibodies resulted in two 
clones that recognized the ECD (32f, 67b), but unfortunately they reacted only 
the recombinant protein and not with endogenous teneurin-4 in cell and tumor 
lysates. Currently, monoclonal antibodies against the ICD are being screened 
and hopefully will work in WB analysis and in IHC, which can then be used to 
confirm the results I describe below.  
 
Thus, all the results so far were obtained with the polyclonal ECD 
antibodies. The antibodies were first tested on recombinant protein, and 
subsequently on cell and tumor lysates. In brain tumors, a main band of about 
200 kDa was observed, which was not present in the controls including the ECD 
antibodies preabsorbed with the antigen and the preimmune serum (Figure 19). 
For a full-length teneurin-4, a molecular weight of >300 kDa is expected, 
therefore the observed band may correspond to a shed ECD. Subsequently, 
three samples of normal brain (total brain, cortex, and cerebellum) were 
compared to three tumors with varying expression levels of teneurin-4, which 
was found to be nearly absent in normal brain. In cerebellum and cortex, faint 
bands with lower molecular weights than the bands present in the tumor 
samples were observed at >120 kDa (Figure 19). 
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Figure 19: Characterization of antibodies and comparison normal brain with 
tumors. 
A) Testing the specificity of the ECDA polyclonal antibody on brain tumor lysate: Left lane 
ECDA 1:1000, middle lane ECDA preabsorbed with antigen 1:1000, right lane preimmune 
serum 1:1000. B) Comparison of teneurin-4 expression in three samples of normal brain 
(brain, cortex, cerebellum), and three brain tumors with different teneurin-4 expression 
levels (221, 225, 299). 
 
 
 Finally, three different panels of brain tumors were analyzed by western 
blotting using the ECDA antibody. Two panels of brain tumors included different 
types of tumors, astrocytoma, oligodendroglioma and glioblastoma (Figure 20). 
Teneurin-4 was found to be overexpressed in all types, particularly in 
glioblastoma (e.g. BS 117T, BS 229, 116, 117). The astrocytomas present in the 
two panels showed lower expression of teneurin-4 (BS 177T, BS 246T, A96, 
A103, A127). The presence of teneurin-4 in oligodendroglioma appeared to be 
intermediate (BS 189, BS 271, 22OG, 92OG). In general, teneurin-4 expression 
varied between individual tumor samples. A third panel of brain tumors 
consisting of 15 glioma samples was analyzed, where almost all tumors 
expressed teneurin-4, some at very high levels (Figure 21). In most samples, a 
band or a smear was observed on top of the lane in addition to the 200 kDa 
band, which may represent glycosylated and/or dimerized teneurin-4. 
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Figure 20: WB analysis of two panels of different brain tumors. 
A) Four glioblastoma (BS 117T, BS 221, BS 225, BS 229), two astrocytoma (BS177T, BS 
246T) and two oligodendroglioma (BS 189, BS 271) were analyzed for teneurin-4 
expression. B) A second panel of brain tumors included three astrocytomas (A96, A103, 
A127), three glioblastoma (116, 117, 216) and two oligodendroglioma (22OG, 92OG). 
Vinculin serves as a loading control. 
 
 
 
Figure 21: WB analysis of a panel of glioblastomas. 
A third panel or brain tumors was analyzed for teneurin-4 expression, all 15 samples are 
derived from glioblastomas patients. Vinculin serves as a loading control. 
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5.4.3 IHC of brain tumors 
 
 Frozen sections of brain tumors were obtained, which were stained with 
the EGFA antibody to find out if the tumor cells themselves expressed teneurin-
4, or if it was rather derived from stromal cells. Since the number of tissue 
slides was very limited, standard staining conditions were used and it was not 
possible to optimize the staining protocol. Several tumors exhibited a very 
strong staining of tumor cells and blood vessels, which is also weakly present in 
the preimmune control. However, these tumors consisted of large regions of 
necrosis (labeled N in the H&E staining picture) characteristic of progressing 
glioblastomas, which were strongly but unspecifically stained. In other tumors, 
the teneurin-4 staining was restricted to the blood vessels while the tumor cells 
themselves were not positive for teneurin-4 (Figure 22). However, the integrity 
of the frozen tissue sections was far from optimal and the morphology of the 
tumors is poorly preserved. Therefore, it is difficult to draw conclusions based 
on these tissue sections.  
 
Several tumors exhibited staining of blood vessels (tumor 103A, tumor 
96A, tumor 92OG, tumor 271, tumor 221, tumor 225), suggesting a role for 
teneurin-4 in angiogenesis (Figure 23). It appeared that not only the endothelial 
cells were stained, but the entire blood vessel wall, suggesting that the 
teneurin-4 ECD may be shed and incorporated into the basal membrane 
surrounding the blood vessels. It will be interesting in the future to confirm the 
specificity of this staining and to determine if the teneurin-4 present around the 
blood vessels is derived from tumor cells or from endothelial cells. 
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Figure 22: Teneurin-4 IHC in brain tumors. 
Certain tumors were strongly positive for teneurin-4 (e.g. tumor 206, tumor 164); 
however they exhibited large regions of necrosis (labeled N in the H&E staining picture) 
that are stained. Other tumors were less positive for teneurin-4, and staining was more 
restricted to blood vessels (tumor 92OG, tumor 271). The teneurin-4 staining appears 
brown and the cell nuclei are counterstained with blue dye. H&E staining is depicted 
where available. 
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Figure 23: Teneurin-4 staining is present on blood vessels. 
Blood vessels were stained in all tumors (e.g. tumor 221), and in most tumors teneurin-4 
was restricted to blood vessels (tumor 103A, tumor 96A, tumor 92OG, tumor 271, tumor 
225). This staining was observed in all types of tumors, astrocytomas (tumor 103A, 
tumor 96A) oligodendrogliomas (tumor 92 OG, tumor 271) and glioblastomas (turmo 
221, tumor 225).  
 
 
5.4.4 Comparison between WB analysis and IHC  
 
The staining intensities on WBs and on tissue sections were compared 
relative and scored as absent (-), very low (-/+), medium (+), strong (++) and 
very strong (+++). Overall, there was a good correlation between WB analysis 
and IHC staining (Table 9). Higher levels of teneurin-4 protein was detected in 
glioblastoma by both methods, however this might be due to the large regions 
of necrosis which are certainly also present in protein lysates. The necrotic areas 
might also explain why on protein level as detected with the ECD antibody, 
seemingly more teneurin-4 was detected than in the microarray analysis. 
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Brain 
tumor 
tumor 
type WB 
IHC 
staining 
116 GBM +++ ++ 
117 GBM ++ ++ 
164 GBM + +++ 
206 GBM +++ +++ 
221 GBM -/+ +++ 
225 GBM + ++ 
226 GBM +++ +++ 
229 GBM +++ ++ 
232 GBM ++ +++ 
242 GBM +++ +++ 
103A AII -/+ + 
177 AII - -/+ 
246 AII -/+ + 
96A AIII + + 
127 AIII + + 
22OG OG - + 
92OG OG ++ ++ 
189 OGIII + + 
271 OGIII ++ ++ 
 
Table 9: Comparison between WB analysis and IHC of teneurin-4 expression. 
The intensities of staining on immunoblots and tissue section were scored relative to the 
other tumor samples as absent (-), very low (-/+), medium (+), strong (++) and very 
strong (+++). 
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6.  DISCUSSION 
 
The potential role of teneurins in neuronal development and the 
establishment of appropriate synaptic connections as well as our teneurin 
signaling hypothesis are already discussed in my publication “Teneurin-1 is 
expressed in interconnected regions of the developing brain and is processed in 
vivo”127 and my review “Teneurins, a transmembrane protein family involved in 
cell communication during neuronal development”115. Thus, the discussion of 
these two aspects is covered by my paper and my review, and only as short 
section discussing the unpublished results of teneurin-4 expression is added. 
This is followed by two sections discussing in detail the unpublished parts of 
teneurin-1 as a candidate gene for XLMR and teneurin-4 as a marker for brain 
tumors.  
 
 
 
6.1 Teneurins in neuronal development and our teneurin 
 signaling hypothesis 
 
Visions & Reflections Minireview:  
“Teneurins, a transmembrane protein family involved 
in cell communication during neuronal development.”
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6.2 Teneurin-4 in chick CNS and limb development 
 
 
 The domain architecture and amino acid sequence of the four vertebrate 
teneurin paralogs is highly conserved and teneurin-4 is expressed at similar 
sites as the other teneurins. Teneurin-4 is expressed strongly in specific parts of 
the CNS and in non-neuronal sites of pattern formation such as the limb bud, as 
it has been previously described other teneurins. Furthermore, by using 
teneurin-4 ICD antibodies, I could detect N-terminal processing products, as it 
was already observed for teneurin-1127 and teneurin-2 (unpublished 
observation). This suggests that the proposed signaling mechanism including 
processing by RIP is conserved among the four vertebrate teneurin paralogs. 
 
Since the expression patterns of teneurins in the brain have already been 
discussed in detail, I will focus this section on the discussion of teneurin 
expression patterns in the developing limb. Teneurin-4 exhibited a particularly 
interesting expression pattern in the developing limb. It was present in both 
crucial signaling centers: the AER at the tip of the limb bud and in the ZPA near 
the base of the developing limb. FGFs expressed by the AER induce the 
proliferation of underlying mesenchymal cells and distal outgrowth of the limb 
bud; and cells of the ZPA secrete Shh to determine anterior-posterior 
patterning. Previously, teneurin-2 was shown to be expressed in the AER117 and 
induced by FGF8 in limb bud cultures, suggesting that teneurin-2 is induced by 
FGFs expressed in the limb bud in vivo. Thus, teneurin-4 expression may be 
regulated by FGF signaling as well. During AER formation, teneurin-2 and -4 
may function as adhesion molecules facilitating the migration of induced AER 
precursors to the future AER site or their subsequent compaction. In the ZPA, 
the expression of teneurin-4 may be induced by Shh, as it is suggested to be 
the case in the Drosophila eye imaginal disc. The expression of ten-m in the 
morphogenetic furrow is strongly reduced in a mutant carrying a hypomorphic 
Hedgehog allele, implying that ten-m is downstream of hedgehog signaling142. 
As a putative adhesion molecule, teneurin-4 may function to promote adhesion 
of Shh-expressing cells in the ZPA to maintain the integrity of this signaling 
center. Thus, teneurin-4 appears to be important in signaling centers in the limb 
bud regulating proximo-distal as well as anterior-posterior axis specification.  
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6.3 Is teneurin-1 a candidate gene for XLMR? 
 
 
 When this project was started in 2005, several XLMR families with 
unknown cause linked to Xq25 existed, and none of the 45 XLMR genes known 
at that time was located in Xq25 except OCRL1 causing the Lowe-Syndrome70. 
In the meantime, the number of known XLMR genes has almost doubled, and 
three new genes in Xq25 have been identified: GRIA372, ZDHHC971 and 
UPF3B143. At the end of 2007, the genetic cause was still unknown for 133 XLMR 
families59. We hypothesized that teneurin-1 located at Xq25 is a promising 
candidate gene because of its suggested function in synaptic connectivity. 
Defects in neuronal connectivity are thought to underlie mental retardation, 
particularly when gross brain abnormalities are absent69. In addition, several 
genes that have been shown to interact with teneurin-1 are implicated as XLMR 
genes, such as Syn173 and MBD175, both of which bind to the teneurin-1 ICD76 
(and unpublished observation). Moreover, several factors that are thought to 
regulate teneurin expression are crucial for brain development, such as EMX2, 
ZIC and FGFs68. 
 
 Unfortunately, no obvious disease causing mutation was found in the 
analysis of the coding and exon-flanking sequence of teneurin-1 in 21 XLMR 
patients linked to Xq25. Of 27 alterations found, 21 were located in non-coding 
regions and 6 within the exon-coding sequence. While 16 corresponded to 
known SNPs, 11 may represent novel SNPs, particularly those which were found 
in several patients (flanking regions of exon 18, exon 20 and exon 26). There 
were 5 synonymous nucleotide exchanges in the coding region, one in exon 29 
beeing novel, and one non-synonymous resulting in the exchange of a 
methionine with a threonine in exon 6 (SNP rs2213591). No alteration was 
detected in the splice consensus sequence, and most nucleotide exchanges 
found in the 5’upstream and 3’untranslated region corresponded to known 
SNPs. One patient (p) exhibited an accumulation of SNPs in the 5’upstream 
region, which were however not present in two affected brothers and therefore 
can be ruled out as the cause for XLMR in this family.   
 
                                                                                 Discussion        
 
- 102 -
   
 The fact that no mutations likely to cause XLMR were found in the coding 
sequence of the patients analyzed does not exclude that a mutation in a 
regulatory sequence causes misexpression of the teneurin-1 gene. However this 
is difficult to predict, particularly since the promoter of teneurin-1 has not yet 
been characterized. Preliminary experiments show that the teneurin-1 gene 
contains an untranslated first exon that is located about 250kb upstream of the 
first translated exon in a region containing CpG islands (unpublished 
observation). Therefore, it is likely that the promoter of teneurin-1 is located far 
more upstream than assumed for my patient sequence analysis, or that 
alternative promoters exist. Since regulatory sequences are often located in the 
first intron, it will be very difficult to identify regions that are important for 
teneurin gene regulation. Furthermore, alternative splicing could result in the 
transcription of additional coding exons that were not included in my analysis. 
The alignment of the predicted human teneurin-1 to -4 paralogs which are 
highly conserved in their amino acid sequence suggests the existence of 
additional exons that were not part of the reference sequence used for this 
analysis, e.g. between exon 3 and exon 4 and between exon 20 and exon 21. 
Thus, a mutation located on one of those exons would have escaped my 
analysis. In addition, although only the nucleotides directly at the exon-intron 
boundaries are highly conserved, those further away from the splice site may 
also affect regulation of splicing, and it is difficult to predict whether such a 
mutation would affect splicing of teneurin-1. Both the levels of teneurin-1 
expression and regulation of (alternative) splicing can be studied using 
immortalized lymphocytes from XLMR patients by RT-PCR or Q-PCR. These 
methods have already been successful in the identification of XLMR splice site 
mutations in the past, e.g. in the case of HADH2144. However none of the 
alterations I have identified seemed promising enough to undertake such 
experiments. Besides, since gene expression and splicing is often regulated in a 
tissue-specific manner there are potentially differences between lymphocytes 
and brain. Finally, ncRNAs or miRNAs that are present in the teneurin-1 locus 
that regulate the expression of teneurin-1 or exert other biological functions 
may be affected by a mutation. Such an ncRNA has been identified in an intronic 
region of the teneurin-3 gene145, and several ncRNAs are predicted in the odz1 
locus (e.g. AK086544). 
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 The SNPs that are present in the teneurin-1 coding region and result in 
amino acid exchanges (rs2213591 in exon 6, rs16999334 and rs6649271 in 
exon 11 and rs35405207 in exon 23) could potentially affect teneurin-1 function 
in individuals carrying these SNPs. If teneurin-1 is important for the 
development of appropriate neuronal connectivity, these SNPs may affect brain 
function in humans. An additional SNP is located in exon 23 (rs35405207) and 
inserts a G nucleotide, this results in a frame shift and truncation of the 
teneurin-1 protein in the ECD. Since no validation or frequency data is available 
for this SNP, it would be interesting to confirm its occurrence in the human 
population and test whether it is associated with any phenotype of altered brain 
function. In addition even a silent SNP may alter protein function, as it has been 
shown in the case of MDR1 gene. In such a case, the of an alternative codon 
altered the speed of translation and protein folding which finally affected protein 
function146. 
 
 
 X-linked lymphoproliferative disease (XLP) is characterized by extreme 
sensitivity to the Epstein-Barr virus (EBV) resulting in a complex phenotype 
involving severe infections and malignant lymphoma caused by mutations in the 
SH2D1A/SAP or XIAP/BIRC4 genes147,148. Recently, a family with XLP and 
chronic active inflammatory gastric lesions was described, which carries a 3 Mb 
deletion comprising SH2D1A, the adjacent teneurin-1 gene and two other 
predicted genes149. Thus, if these patients do not have mental retardation in 
addition of these symptoms, it is very unlikely that teneurin-1 is involved in 
XLMR except in the case that a mutated teneurin-1 would exhibit a gain-of-
function phenotype causing XLMR. However, it is also possible that these 
patients do have subtle defects in brain function, as it was described for the 
teneurin-3 knockout mice, which show an impairment of binocular vision129. 
Such a minor phenotype may not be diagnosed, particularly in XLP patients that 
suffer from a severe and fatal disease. 
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6.4 Is teneurin-4 a marker for cancer? 
 
 
The data of a microarray study analyzing brain tumor samples performed 
in the Hemmings lab showed high and consistent upregulation of teneurin-4 and 
prompted us to generate the tools to investigate the expression of human 
teneurin-4 in brain tumors and possibly other types of cancers. Teneurin-4 was 
the only teneurin that was upregulated in this study while teneurin-2 and 
teneurin-3 levels in contrast were the same for normal brain and tumors. For 
teneurin-1 no conclusion is possible because the probe on the microarray did 
not detect any significant expression and thus no data was available. Therefore, 
we focused on teneurin-4 as a potential brain tumor marker. 
 
 
The microarray data are a good indication, but it was important to 
confirm the overexpression of teneurin-4 on protein levels. Therefore, I 
generated recombinant proteins for the production of polyclonal and monoclonal 
antibodies recognizing the ICD and ECD of teneurin-4. The goal was not only to 
develop the tools to test teneurin-4 expression on protein level, but also to be 
able to study teneurin processing as it is suggested by our teneurin signaling 
hypothesis. To date, only polyclonal antibodies recognizing the ECD were 
successfully obtained, and potentially useful monoclonal antibodies recognizing 
the ICD are being evaluated. By using the polyclonal ECD antibodies, I could 
confirm a strong overexpression of teneurin-4 in all types of brain tumors, 
including astrocytoma, oligodendroglioma and glioblastoma, compared to three 
samples of normal brain both by WB analysis and IHC of brain tumor sections. 
However, several things need to be considered: First, more samples of normal 
brain would be needed to make a statistically significant statement, especially 
since expression of teneurin-4 in the adult brain may vary strongly depending 
on the exact anatomical location, as suggested by the very specific teneurin-4 
expression during brain development in chick an mouse. Second, it is very 
important to confirm the results using a different antibody, as it is difficult to 
prove the specificity of the band detected by the polyclonal ECD antibody. 
Hopefully, the monoclonal ICD antibodies will soon be available confirm 
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teneurin-4 overexpression independently. Moreover, on tissue sections the ECD 
antibody stains non-specifically large regions of necrosis, which certainly are 
also present in the protein lysates. Indeed, the correlation between the WB 
analysis and IHC of glioblastoma may be derived from the extent of necrosis in 
the individual tumors rather than from specific teneurin-4 expression. This may 
also be the reason why on WB and IHC, glioblastomas show higher teneurin-4 
expression than astrocytomas, whereas the opposite is true for the microarray 
data. Third, the quality of the frozen brain tumor sections is not sufficient, 
because in addition of the large areas of necrosis, there are regions with 
freezing and thawing artifacts. Necrosis is an intrinsic characteristic of 
progressing glioblastomas and thus cannot be avoided, whereas the brain tumor 
tissue will certainly be better preserved on paraffine sections. Therefore, it is 
important to test the polyclonal ECD and monoclonal ICD antibodies on paraffine 
sections and establish a reliable staining protocol. For this purpose, normal 
human fetal brain may be useful, as teneurin-4 is certainly expressed in some 
regions of the brain. Fourth, whereas blood vessels were stained in all tumors 
analyzed by IHC, some tumors exhibited also staining of tumor cells 
themselves. It will be important to confirm the specificity of the blood vessel 
staining and to determine if teneurin-4 is expressed by the tumor itself, or by 
endothelial cells, for example by in-situ hybridization. Even the teneurin-4 that 
is found around blood vessels may be produced by tumor cells and subsequently 
processed resulting in the release of the ECD, which then incorporates into the 
basal membrane that is present around the blood vessels. The furin cleavage 
site that was shown to mediate ECD shedding in chick teneurin-2116 is also 
conserved in human teneurin-4. In C.elegans, genetic interactions between 
teneurin and components of the BM as well as BM receptors on the cell surface 
have been described, and the BM integrity is affected by BM mutants114. In 
developing chick embryos, teneurin-2 was found to colocalize with laminin, 
suggesting that it is incorporated into the BM81. Depending on the cell type 
expressing teneurin-4, different sets of experiments have to be performed to 
analyze the function of teneurin-4 in brain tumors. Fifth, it appears that 
teneurins are described to be mainly expressed in neurons and not in glial cells, 
whereas astrocytomas, oligodendrogliomas and glioblastomas are all of glial 
origin. However, co-staining of a glial cell marker and teneurin has not yet been 
performed to exclude that teneurins are expressed also in glial cells during 
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devlopment. Conversely, it will be interesting to test the expression of teneurin-
4 in brain tumors of neuronal origin, e.g. neuroblastoma.  
 
 
After the overexpression of teneurin-4 in brain tumors has been 
confirmed, it will be interesting to determine whether teneurin-4 has a function 
in cancer development and progression. To this aim, it will be necessary to clone 
the full-length teneurin-4. It would be interesting to determine if the conserved 
furin cleavage site on the ECD is functional and if this cleavage resulting in ECD 
shedding occurs is regulated or occurs constitutively. This implies that teneurin-
4 activity would not be restricted to the cell membrane, but that it would act as 
a soluble molecule like e.g. the tenascins. Depending on which cells are 
assumed to be affected by the presence of teneurin-4, the cancer cells or the 
endothelial cells, different sets of experiments should be performed. Possibly, 
teneurin-4 may also affect both cell types. If teneurin-4 is suspected to be 
implicated in angiogenesis, HUVEC cells can be used for experiments to perform 
angiogenesis assays, such as the spheroid sprouting assay and the matrigel 
tubule formation assay. Other possible assays for testing the effect of soluble 
teneurin-4 on angiogenesis include the aortic ring assay, chicken chorioallantoic 
membrane assay and matrigel plug assay. If teneurin-4 is expressed in HUVEC 
cells, it would be interesting to see the effects of an RNAi or shRNA knockdown 
on the tube formation capacity of these cells after stimulation with angiogenetic 
factors, such as VEGF. To test the effects of teneurin-4 on tumor cells, a glioma 
or neuroblastoma cell line overexpressing the full length protein can be 
established and used to perform several assays, such as proliferation assay, 
adhesion assay, aggregation assay, migration assay, scratch assay and invasion 
assay. Conversely, if a cell line that normally expresses high levels of teneurin-4 
is identified, the same assays could be performed using siRNA treated sells or a 
stable shRNA knockdown cell line. Finally, it is also conceivable to test the 
function of teneurin-4 in cancer growth in an in-vivo xenograft model by 
injection of cells that overexpress teneurin-4 or are depleted of teneurin-4 by 
shRNA. 
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Cancer type compared to name of study
upregulated in cancer
Glioblastoma normal brain Shai_Brain
B-cell leukemia normal bone marrow Andersson_Leukemia
Carcinoid lung normal lung Battarchajee_Lung
Seminoma normal testis Korkola_Seminoma
Clear cell carcinoma of kidney normal kidney Cutcliffe_Renal
downregulated in cancer
Ovarian endothelial adenocarcinoma normal ovary Hendrix_Ovarian
Ovarian clear cell carcionma normal ovary Hendrix_Ovarian
Ovarian cancer normal cervix Pyeon_Multi_Cancer
upregulated in cancer type
Acute lymphoblastic leukemia Acute myelogenous leukemia Andersson_Leukemia
Acute lymphoblastic leukemia Myelomonocytic leukemia Armstrong_Leukemia
Gastrointestinal stromal tumor other soft tissue tumors Nielsen_Multi_Cancer
Synovial sarcoma other sarcomas Nakayama_Sarcoma
Ovarian carcinoma other carcinomas Bittner_Multi_Cancer
Serous papillary ovarian adenocarcinoma other carcinomas Sh_Multi_Cancer
downregulated in cancer type
Lung adenocarcinoma Small cell lung cancer Bild_Lung
Lung adenocarcinoma Small cell lung cancer Kim_Lung
Ewing sarcoma other sarcomas Baird_Sarcoma
Colon Carcinoma other carcionmas Bittner Multi_cancer
Renal Carcinoma other carcionmas Bittner Multi_cancer
Prostate Carcionma other carcionmas Bittner Multi_cancer
T-cell leukemias B-cell leukemias Schmidt_Leukemia
upregulated with molecular alterations
Leukemia with E2A-PBX1 other leukemias Yeoh_Leukemia
Leukemia with E2A-PBX1 other leukemias Ross_Leukemia
Leukemia with TCF3-PBX1 other leukemias Andersson_Leukemia
Leukemia with TEL-AML other leukemias Yeoh_Leukemia
upregulated in metastatic cancer
Metastatic lung cancer primary cancer Battarcharjee_Lung
downregulated in metastatic cancer
Metastatic melanoma primary cancer Xu_Melanoma  
 
Table 10: Summary of entries for teneurin-4 (odz4) in the oncomine database. 
The results are grouped into comparisons between cancer and normal tissue or cancer 
with other cancer types, and up- or downregulation of teneurin-4, respectively. Listed are 
the type of cancer, the comparison group and the name of the micorarray study. All the 
results listed are statistically significant with a p value of > 0.0001. 
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In the oncomine database, several studies suggest that teneurin-4 is 
overexpressed in a variety of cancers, as summarized in Table 10. Most studies 
use the probes 213273_at or 36078_at, both of which are located in the same 
region and comprise the two last exons of teneurin-4. Several studies report 
overexpression of teneurin-4 in the following cancers compared to normal 
tissues: Glioblastoma, B-cell leukemia, lung carcinoma, seminoma and kidney 
clear cell carcinoma. In contrast, teneurin-4 appears to be downregulated in 
several types of ovarian cancer. Compared to other cancers, teneurin-4 was 
upregulated in acute lymphoblastic leukemia, ovarian carcinoma, serous 
papillary ovarian carcinomas, gastrointestinal tumors ans synovial carcinoma. In 
contrast, teneurin-4 appears to be downregulated in B-cell leukemia, lung 
adenocarcinoma, Ewing Sarcoma, and in carcinomas of the colon, kidney and 
prostate. Very striking is the upregulation of teneurin-4 in leukemias carrying 
the E2A-PBX1, TCF3-PBX1 and TEL-AML translocation. This suggests that 
teneurin-4 may be regulated by PBX1, which acts as a cofactor to regulate Hox-
dependent gene expression during development, particulary since the hox genes 
as well as the teneurins are expressed at sites of pattern formation. Regarding 
teneurin-4 expression in metastatic versus primary cancer, two contradictory 
studies are found, one stating that teneurin-4 is overexpressed in metastatic 
lung cancer, and one that it is downregulated in metastatic melanoma. Thus, 
there is no clear indication so far that teneurin-4 may be implicated in cancer 
progression. Because several studies in the oncomine database suggest that 
teneurin-4 may overexpressed a variety of cancers, it will be worthwile to 
investigate the expression of teneurin-4 in other cancers and normal tissues, 
this can be done by the staining of a tissue-microarray as soon as a reliable 
antibody and staining protocol are available. 
 
 
 Only teneurin-4 appears to be upregulated in cancer and not the other 
teneurins, as indicated by the brain tumor microarray data and oncomine 
entries. Therefore, it is an interesting question if teneurin-4 may have an 
additional function that is missing in the other teneurins that could promote 
cancer development, for example in the maintenance or proliferation of stem 
cells. The SVZ of the lateral ventricles and the subgranular zone (SGZ) of the 
dentate gyrus are two regions in the rodent brain where adult neurogenesis 
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occurs150. Indeed, teneurin-4 is strongly expressed in both of these regions 
during mouse brain development up to postnatal day 7, whereas the other 
teneurins are only weakly expressed or absent77. Moreover, during 
development, the cortical progenitor cells are generated in the ventricular and 
subventricular zone, coinciding spatially and temporally with teneurin-4 
expression77. In the developing chick, strong teneurin-4 expression was 
detected in the clilary margin of the retina (Figure 12), where the retinal 
progenitor cells which continue proliferation until adulthood reside151.  
 
 
In addition to study the role of teneurin-4 in cancer, a cell line expressing 
teneurin-4 may also be useful as a model to study teneurin signaling. Such a 
model was missing so far as most of our teneurin studies were performed with 
chicken proteins and only very few chicken cell lines exist. To be able to study 
teneurin-4 signaling, it will be important to have specific antibodies for both the 
ICD and the ECD that can be used in WBs and immunofluorescence. Possibly 
shed teneurin-4 ECD could be detected in the medium of teneurin-4 expressing 
cells. Additionally, a wild-type and furin-cleavage site mutated teneurin-4 
construct can be transfected into cells to verify proteolytic processing of the 
ECD. The cells can be fractionated to detect cleaved ICD in the cytoplasimc or 
nuclear fractions, possibly this may be only the case after stimulation with an 
appropriate signal and/or the treatment with proteasome inhibitors, if the ICD is 
very unstable as it is the case for Notch ICD152. To study teneurin signaling, it 
will be crucial to find extracellular ligands for teneurin that may activate the 
teneurins in addition to homophilic interaction, which appears to promote 
teneurin cleavage. This could be done by purification of a recombinant secreted 
protein, e.g the ECD fragment that results after furin cleavage, which then can 
be used to generate a teneurin-4 ECD column for affinity purification of 
interacting proteins from brain protein lysate. In case it is difficult to express the 
entire teneurin-4 ECD, it may also be possible to perform the same experiments 
with recombinant proteins comprising single domains of the ECD, e.g. EGF-like 
repeats or YD-repeats. Such recombinant proteins can also be used to test if 
these domains modulate cell adhesion, cell migration or neurite outgrowth. 
Especially if the overexpression of teneurin-4 in brain tumors and possibly other 
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cancers is confirmed, it will be interesting to elucidate the biological function of 
teneurin-4  and to determine in which signaling pathways it is involved. 
 
6.5 Final conclusions 
 
In the first part of my PhD work, I intended to shed light on the potential 
function and signaling mechanism of the teneurins. A detailed analysis of 
teneurin-1 expression in the brain showed expression in distinct and 
interconnected regions in the brain, suggesting that teneurins may play a role in 
the establishment of appropriate synaptic connectivity. For the first time, 
teneurin processing was studied in-vivo using N-terminal antibodies. By WB 
analysis and IHC of developing chick embryos, N-terminal processing products 
and nuclear ICD of teneurin-1 in developing chick embryos were found. 
Additionally, the ICD was shown to localize to the nucleus in an NLS-dependent 
manner in cultured cells. Data obtained for teneurin-4 also show specific 
expression in interconnected regions in the brain and N-terminal processing 
products, suggesting that the function and signaling mechanism of the four 
vertebrate teneurin paralogs is conserved. 
 
In the second part, I investigated the involvement of teneuirns in human 
disease. Although teneurin-1 is a promising candidate gene for XLMR, no 
disease causing mutation was identified. Since in the meantime a patient with a 
deletion of the teneurin-1 gene was published in XLP patients, it is unlikely that 
teneurin-1 causes a severe XLMR phenotype. Based on microarray analysis that 
showed upregulation of teneurin-4 in brain tumors, antibodies were produced 
and the overerexpression of teneurin-4 was confirmed on protein level. In an 
ongoing project, these findings are being validated with an ICD antibody and the 
function of teneurin-4 in cancer is beein investigated in cell culture. 
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7.  APPENDIX 
 
7.1 Abbreviations 
 
AER   Apical ectodermal ridge (limb bud) 
APC   Adenomatous polyopsis coli 
Array-CGH  Comparative genome hybridization technology 
BM   Basement membrane 
BMP   Bone morphogenetic protein 
CAM   Cell adhesion molecule 
CNS   Central nervous system 
CSPG   Chondroitin sulphate proteoglycan 
dLGN   Dorsal lateral geniculate nucleus 
ECD   Extracellular domain 
ECM   Extracellular matrix 
EGF   Epidermal growth factor 
EGL    External germinal layer (cerebellum) 
En1   Engrailed-1 
FAK   Focal adhesion kinase 
FGF   Fibroblast growth factor 
FISH   Fluorescence in-situ hybridization 
FMR1   Fragile X mental retardation 1 
GAP-43   Growth-associated protein 43 
GBM   Glioblastoma multiforme 
GCL   Ganglion cell layer (retina) 
GCP   Granule cell precursor (cerebellum) 
HSPG   Heparin sulphate proteoglycan 
ICAM   Intercellular adhesion molecule 
ICD   Intracellular domain 
Ig-CAM   Immunoglobulin-like cell adhesion molecule 
IHC   Immunohistochemistry 
INL   Inner nuclear layer (retina) 
IPL   Innter plexiform layer (retina) 
MB   Medulloblastoma 
miRNA   microRNA 
MR   Mental retardation 
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ncRNA   noncoding RNA 
odz1 to -4  Alternative name for teneurin-1 to -4 
OFL   Optic fiber layer (retina) 
ONL   Outer nuclear layer (retina) 
OPL   Outer plexiform layer (retina) 
OT   Optic tectum 
PDGF   Platelet derived growth factor 
PNS   Peripheral nervous system 
POFUT1  Protein-O-fucosyltransferase-1 
RGC   Retinal ganglion cell 
RIP   Regulated intramembrane proteolysis 
S2P   Site-2 protease 
SC   Superior colliculus 
SGFS   Stratum griseum et fibrosum superficiale (OT) 
SHH   Sonic hedgehog 
SNP   Single nucleotide polymorphism 
SPP   Signal peptide peptidase 
SPPL   Signal peptide peptidase-like 
SVZ   Subventricular zone 
TCAP   Teneurin-associated C-terminal peptide 
Ten-1L   C.elegans teneurin homolog, long isoform 
Ten-1S   C.elegans teneurin homolog, short isoform 
Ten-a   Drosophila teneurin homolog 
Ten-m/odz  Drosophila teneurin homolog 
Ten_m1 to -4  Mouse teneurin-1 to-4 
TNF   Tumor necrosis factor 
TM   Transmembrane 
VEGF   Vascular endothelial growth factor 
VZ   Ventricular zone (cortex, cerebellum) 
WB   Western blot 
XLMR   X-linked mental retardation 
XLP   X-linked lymphoproliferative disease 
ZPA   Zone of polarizing activity (limb bud) 
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